{"id":"afatinib","rwe":[{"pmid":"41882274","year":"2026","title":"TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations.","finding":"","journal":"Communications medicine","studyType":"Clinical Study"},{"pmid":"41878697","year":"2026","title":"Fatal Disease Progression Driven by Acquired MET Amplification After EGFR-TKI Therapy in EGFR- and RBM10-Mutant Lung Adenocarcinoma.","finding":"","journal":"Cancer management and research","studyType":"Clinical Study"},{"pmid":"41875675","year":"2026","title":"Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation.","finding":"","journal":"Bioorganic & medicinal chemistry","studyType":"Clinical Study"},{"pmid":"41874451","year":"2026","title":"The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer.","finding":"","journal":"Cancer discovery","studyType":"Clinical Study"},{"pmid":"41872782","year":"2026","title":"EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.","finding":"","journal":"BMC cancer","studyType":"Clinical Study"}],"_fda":{"id":"3a365319-7ba8-4454-8239-7b0e7ff8a18e","set_id":"fd638e5e-8032-e7ca-0179-95e96ab5d387","openfda":{"nui":["N0000175605","N0000175076"],"unii":["41UD74L59M"],"route":["ORAL"],"rxcui":["1430446","1430449","1430451","1430453","1430455","1430457"],"spl_id":["3a365319-7ba8-4454-8239-7b0e7ff8a18e"],"brand_name":["Gilotrif"],"spl_set_id":["fd638e5e-8032-e7ca-0179-95e96ab5d387"],"package_ndc":["0597-0141-30","0597-0137-30","0597-0137-90","0597-0138-30","0597-0138-95"],"product_ndc":["0597-0137","0597-0141","0597-0138"],"generic_name":["AFATINIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AFATINIB"],"pharm_class_epc":["Kinase Inhibitor [EPC]"],"pharm_class_moa":["Protein Kinase Inhibitors [MoA]"],"manufacturer_name":["Boehringer Ingelheim Pharmaceuticals, Inc."],"application_number":["NDA201292"],"is_original_packager":[true]},"version":"20","pregnancy":["8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , GILOTRIF can cause fetal harm when administered to a pregnant woman. There are no available data on the use of GILOTRIF in pregnant women. Administration of afatinib to pregnant rabbits during organogenesis at exposures approximately 0.2 times the exposure in humans at the recommended dose of 40 mg daily resulted in embryotoxicity and, in rabbits showing maternal toxicity, increased abortions at late gestational stages (see Data ) . Advise a pregnant woman of the potential risk to a fetus . The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal development study in rabbits, administration of afatinib to pregnant animals at doses of 5 mg/kg (approximately 0.2 times the exposure by AUC at the recommended human dose of 40 mg daily) or greater during the period of organogenesis caused increased post-implantation loss, and in animals showing maternal toxicity, abortion at late gestational stages. In the same study, at the high dose level of 10 mg/kg (approximately 0.7 times the exposure by AUC at the recommended human dose of 40 mg daily), there were reduced fetal weights, and increases in the incidence of runts, as well as visceral and dermal variations. In an embryo-fetal development study in rats, there were skeletal alterations consisting of incomplete or delayed ossifications and reduced fetal weight at a dose of 16 mg/kg (approximately twice the exposure based on AUC at the recommended human dose of 40 mg daily)."],"overdosage":["10 OVERDOSAGE Overdose was reported in 2 healthy adolescents each of whom ingested 360 mg of GILOTRIF (as part of a mixed-drug ingestion) resulting in nausea, vomiting, asthenia, dizziness, headache, abdominal pain, and elevated amylase [<1.5 times upper limit of normal (ULN)]. Both subjects recovered."],"description":["11 DESCRIPTION GILOTRIF tablets contain afatinib, a tyrosine kinase inhibitor which is a 4-anilinoquinazoline. Afatinib is presented as the dimaleate salt, with the chemical name 2-butenamide, N -[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3 S )-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2 E )-, (2 Z )-2-butenedioate (1:2). Its structural formula is: Afatinib dimaleate is a white to brownish yellow powder, water soluble and hygroscopic, with an empirical formula of C 32 H 33 ClFN 5 O 11 , and a molecular weight of 718.1 g/mol. GILOTRIF tablets for oral administration are available in 40 mg, 30 mg, or 20 mg of afatinib (equivalent to 59.12 mg, 44.34 mg, or 29.56 mg afatinib dimaleate, respectively). The inactive ingredients of GILOTRIF are the following: Tablet Core: lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate and Coating: hypromellose, polyethylene glycol, titanium dioxide, talc, polysorbate 80, FD&C Blue No. 2 (40 mg and 30 mg tablets only). Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING GILOTRIF tablets are available as follows: 40 mg: light blue, film-coated, round, biconvex, bevel-edged tablets debossed with \"T40\" on one side and the Boehringer Ingelheim company symbol on the other side. Unit of use bottles of 30 NDC: 0597-0138-30 30 mg: dark blue, film-coated, round, biconvex, bevel-edged tablets debossed with \"T30\" on one side and the Boehringer Ingelheim company symbol on the other side. Unit of use bottles of 30 NDC: 0597-0137-30 20 mg: white to slightly yellowish, film-coated, round, biconvex, bevel-edged tablets debossed with \"T20\" on one side and the Boehringer Ingelheim company symbol on the other side. Unit of use bottles of 30 NDC: 0597-0141-30 Storage Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense medication in the original container to protect from exposure to high humidity and light."],"geriatric_use":["8.5 Geriatric Use LUX-Lung 3 did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In LUX-Lung 8, 53% of the 398 patients randomized to receive afatinib were 65 years of age or older and 11% were 75 years or older. In an exploratory subgroup analysis of LUX-Lung 8, the hazard ratio for overall survival (OS) in patients less than 65 years old was 0.68 (95% CI: 0.55, 0.85) and in patients 65 years or older was 0.95 (95% CI: 0.76, 1.19). No overall differences in safety were observed between patients 65 years and older and younger patients."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of GILOTRIF in pediatric patients have not been established. The safety and efficacy of afatinib were assessed, but not established, in a single-arm, open-label, multicenter trial [NCT02372006] which included 37 pediatric patients 2 to <17 years of age with recurrent/refractory solid tumors with known ErbB pathway deregulation who received 80% of the adult dose per body surface area. No new safety signals were observed in pediatric patients in this trial. In these 37 patients, the pharmacokinetic parameters were within range of values in adults."],"effective_time":"20251113","clinical_studies":["14 CLINICAL STUDIES 14.1 EGFR Mutation-Positive, Metastatic NSCLC The efficacy of GILOTRIF for the first-line treatment of patients with EGFR mutation-positive, metastatic [Stage IV and Stage IIIb with pleural and/or pericardial effusion as classified by the American Joint Commission on Cancer (AJCC, 6th edition)] NSCLC was established in a randomized, multicenter, open-label trial (LUX-Lung 3 [NCT00949650]). Patients were randomized (2:1) to receive GILOTRIF 40 mg orally once daily (n=230) or intravenous pemetrexed (500 mg/m 2 ) plus cisplatin (75 mg/m 2 ) once every 21 days for up to 6 cycles (n=115). Randomization was stratified according to EGFR mutation category (exon 19 deletion vs exon 21 L858R vs other) and race (Asian vs non-Asian). The major efficacy outcome was progression-free survival (PFS) as assessed by an independent review committee (IRC). Other efficacy outcomes included overall response rate (ORR) and OS. EGFR mutation status was prospectively determined for screening and enrollment of patients by a clinical trial assay (CTA). Tumor samples from 264 patients (178 randomized to GILOTRIF and 86 patients randomized to chemotherapy) were tested retrospectively by the companion diagnostic therascreen ® EGFR RGQ PCR Kit, which is FDA-approved for selection of patients for GILOTRIF treatment. Among the patients randomized, 65% were female, median age was 61 years, baseline ECOG performance status (PS) was 0 (39%) or 1 (61%), 26% were White and 72% were Asian. The majority of the patients had a tumor sample with an EGFR mutation categorized by the CTA as either exon 19 deletion (49%) or exon 21 L858R substitution (40%), while the remaining 11% had other mutations. A statistically significant improvement in PFS as determined by the IRC was demonstrated for patients randomized to GILOTRIF compared with those randomized to chemotherapy. See Table 5 and Figure 1 . There was no statistically significant difference for OS between the treatment arms at the final pre-planned analysis. Table 5 Efficacy Results in LUX-Lung 3 GILOTRIF (N=230) Pemetrexed/Cisplatin (N=115) *Stratified by EGFR mutation status and race. HR=hazard ratio; CR=complete response; PR=partial response Progression-Free Survival by IRC Number of Deaths or Progressions, N (%) 152 (66.1%) 69 (60.0%) Median Progression-Free Survival (months) 11.1 6.9 95% CI (9.6, 13.6) (5.4, 8.2) HR (95% CI) 0.58 (0.43, 0.78) Stratified Log-Rank Test p-value* <0.001 Overall Survival Number of Deaths, N (%) 140 (60.9%) 73 (63.5%) Median Overall Survival (months) 28.2 28.2 95% CI (24.6, 33.6) (20.7, 33.2) HR (95% CI) 0.88 (0.66, 1.17) Stratified Log-Rank Test p-value* 0.39 Overall Response Rate (CR + PR) by IRC N (%) 116 (50.4%) 22 (19.1%) Response Duration Median (months) 12.5 6.7 Figure 1 Kaplan-Meier Curve for PFS by Independent Review by Treatment Group in LUX-Lung 3 Pre-specified exploratory subgroup analyses were conducted according to the stratification factor of EGFR mutation category. See Figure 2 and text below Figure 2. Figure 2 Forest Plots of PFS and OS by EGFR Mutation Subgroups in LUX-Lung 3 Overall Response Rate in Other EGFR Mutations The efficacy of GILOTRIF in patients with NSCLC harboring non-resistant EGFR mutations (S768I, L861Q, and G719X) other than exon 19 deletions or exon 21 L858R substitutions was evaluated in a pooled analysis of such patients enrolled in one of three clinical trials (LUX-Lung 2 [NCT00525148], LUX-Lung 3 [NCT00949650], and LUX-Lung 6 [NCT01121393]). LUX-Lung 2 was a single arm, multicenter study of afatinib 40 or 50 mg orally once daily until disease progression or intolerable side effects. EGFR status was determined by bi-directional Sanger sequencing of tumor tissue. LUX-Lung 3 was a randomized, multicenter study comparing treatment with afatinib 40 mg orally once daily to intravenous cisplatin 75 mg/m 2 plus pemetrexed 500 mg/m 2 every 21 days for up to 6 cycles. EGFR status was determined by the therascreen ® EGFR RGQ PCR Kit. LUX-Lung 6 was a randomized, multicenter study comparing treatment with afatinib 40 mg to intravenous gemcitabine 1000 mg/m 2 on day 1 and day 8 plus cisplatin 75 mg/m 2 on day 1 of a 3-week schedule for up to 6 cycles. EGFR status was determined by the therascreen ® EGFR RGQ PCR Kit. Among the 75 GILOTRIF-treated patients with uncommon EGFR mutations, 32 patients had a non-resistant EGFR mutation. Among the 32 patients with a confirmed non-resistant EGFR mutation, the median age was 60.5 years (range 32-79), 66% were female, 97% were Asian, 3% were other races, 38% had an ECOG PS of 0, 63% had an ECOG PS 1, 66% were never smokers, 28% were former smokers, and 6% were current smokers. Baseline disease characteristics were 97% Stage IV disease, 3% Stage IIIb disease, and 88% had received no prior systemic therapy for advanced or metastatic disease. The number of patients, the number of responders, and durations of response in subgroups defined by identified mutation(s) are summarized in Table 6. Table 6 IRC-Assessed Responses in Patients with NSCLC Harboring EGFR Mutations G719X, L861Q, and/or S768I from LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 EGFR Mutation Number of GILOTRIF Treated Patients (N=32) Number of Confirmed Responses (N=21) Duration of Response (months) (N=21) + response ongoing at time of censoring S768I 1 1 37.3 S768I and G719X 5 4 4.1, 13.2, 15.2, 29.5+ S768I and L858R 2 1 34.5+ G719X 8 6 5.7+, 8.1, 9.6, 23.5+, 25.2, 31.8+ G719X and L861Q 3 2 2.8+, 6.8 L861Q 12 7 2.8, 4.0, 4.1, 8.3+, 12.9, 15.2, 20.6 L861Q and Del 19 1 0 NA Figure 1 Figure 2 14.2 Previously Treated, Metastatic Squamous NSCLC The efficacy and safety of GILOTRIF were demonstrated in a randomized, multicenter, open-label, active-controlled study (LUX-Lung 8 [NCT01523587]). Patients were required to have histologically documented, metastatic squamous NSCLC and have experienced disease progression following an adequate course (≥4 cycles) of a platinum-based doublet chemotherapy regimen. Patients were randomized (1:1) to receive GILOTRIF 40 mg or erlotinib 150 mg orally once daily until progression. Randomization was stratified by region (Eastern Asia vs other). The major efficacy outcome measure was PFS as assessed by an IRC using RECIST v 1.1. Additional efficacy outcome measures were OS and ORR as assessed by IRC. Baseline patient demographics of the 795 patients were: median age 64 years (range: 35 to 88); 73% White; 24% Asian; 84% male; 33% ECOG PS 0 and 67% ECOG PS 1; and 95% current or former smokers. With regard to tumor characteristics, 96% had squamous cell histology and 3.5% had mixed cell histology. All patients received platinum-based doublet therapy. The study demonstrated a statistically significant improvement in PFS and OS for patients randomized to GILOTRIF as compared with erlotinib (see Table 7 and Figure 3 ). Table 7 Efficacy Results in LUX-Lung 8 GILOTRIF Erlotinib *Log-rank test stratified by region. HR=hazard ratio Overall Survival N=398 N=397 Number of Deaths, N (%) 307 (77%) 325 (82%) Median overall survival (months) 7.9 6.8 95% CI (7.2, 8.7) (5.9, 7.8) HR (95% CI) 0.81 (0.69, 0.95) p-value* 0.008 Progression-Free Survival (PFS) by IRC N=335 N=334 Number of Events, N (%) 202 (60%) 212 (64%) Median PFS (months) 2.4 1.9 95% CI (1.9, 2.9) (1.9, 2.2) HR (95% CI) 0.82 (0.68, 0.998) p-value* 0.0427 Overall Response Rate (ORR) by IRC N=335 N=334 ORR 3% 2% (95% CI) (1.7, 5.8) (0.8, 4.3) Figure 3 Kaplan-Meier Curves of Overall Survival in LUX-Lung 8 Figure 3"],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology The effect of multiple doses of GILOTRIF (50 mg once daily) on the QTc interval was evaluated in an open-label, single-arm study in patients with relapsed or refractory solid tumors. No large changes in the mean QTc interval (i.e., >20 ms) were detected in the study."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Following oral administration of GILOTRIF tablets, time to peak afatinib plasma concentrations (T max ) is 2 to 5 hours. Maximum concentration (C max ) and area under the concentration-time curve from time zero to infinity (AUC 0-INF ) values increased slightly more than dose proportional in the range of 20 to 50 mg. The geometric mean relative bioavailability of 20 mg GILOTRIF tablets was 92% as compared to an oral solution. Steady-state plasma concentrations are achieved within 8 days of repeat dosing of GILOTRIF resulting in an accumulation of 2.8-fold for AUC and 2.1-fold for C max . Effect of Food A high-fat meal decreased C max by 50% and AUC 0-INF by 39% relative to the fasted condition [see Dosage and Administration (2.2) ] . Distribution In vitro binding of afatinib to human plasma proteins is approximately 95%. Elimination The elimination half-life of afatinib is 37 hours after repeat dosing in cancer patients. Metabolism Covalent adducts to proteins are the major circulating metabolites of afatinib and enzymatic metabolism of afatinib is minimal. The metabolites formed by CYP450-dependent reactions were approximately 9% of the total metabolic turnover in sandwich-cultured human hepatocytes. Approximately 2% of the afatinib dose was metabolized by FMO3; the CYP3A4-dependent N-demethylation was not detected. Excretion In humans, excretion of afatinib is primarily via the feces (85%) with 4% recovered in the urine following a single oral dose of [ 14 C]-labeled afatinib solution. The parent compound accounted for 88% of the recovered dose. Specific Populations Based on the population pharmacokinetic analysis, weight, gender, age, and race do not have a clinically important effect on exposure of afatinib. Patients with Renal Impairment A pharmacokinetic study was conducted in 14 subjects with normal (eGFR ≥90 mL/min/1.73 m 2 ) renal function, 8 subjects with moderate (eGFR 30 to 59 mL/min/1.73 m 2 ) and 8 subjects with severe (eGFR 15 to 29 mL/min/1.73 m 2 ) renal impairment. All subjects received a single 40 mg oral dose of GILOTRIF. The geometric mean AUC INF for afatinib was 50% higher in subjects with severe renal impairment and was 22% higher in subjects with moderate renal impairment as compared to subjects with normal renal function. Geometric mean C max was 22% higher in subjects with severe renal impairment and was comparable in subjects with moderate renal impairment to subjects with normal renal function [see Dosage and Administration (2.4) , Use in Specific Populations (8.6) ] . GILOTRIF has not been studied in patients with eGFR <15 mL/min/1.73 m 2 or on dialysis. Patients with Hepatic Impairment Mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment had no influence on the afatinib exposure following a single dose of GILOTRIF. Subjects with severe (Child Pugh C) hepatic impairment have not been studied [see Use in Specific Populations (8.7) ] . Drug Interactions Studies Clincial Studies Effect of P-gp Inhibitors and Inducers on Afatinib: The effect of ritonavir dosing time relative to a single oral dose of GILOTRIF was evaluated in healthy subjects taking 40 mg of GILOTRIF alone as compared to those after ritonavir (200 mg twice daily for 3 days) co-administration at 6 hours after GILOTRIF administration. The relative bioavailability for AUC 0-INF and C max of afatinib was 119% and 104% when co-administered with ritonavir, and 111% and 105% when ritonavir was administered 6 hours after taking GILOTRIF. In another study, when ritonavir (200 mg twice daily for 3 days) was administered 1 hour before a 20 mg single dose of GILOTRIF, exposure to afatinib increased by 48% for AUC 0-INF and 39% for C max [see Drug Interactions (7) ]. Pre-treatment with a potent inducer of P-gp, rifampicin (600 mg once daily for 7 days) decreased the plasma exposure to afatinib by 34% (AUC 0-INF ) and 22% (C max ) [see Drug Interactions (7) ] . In Vitro Studies Effect of Afatinib on P-gp: Based on in vitro data, afatinib is an inhibitor of P-gp. Interaction of Afatinib with BCRP: Based on in vitro data, afatinib is a substrate and an inhibitor of the transporter BCRP. Effect of Afatinib on CYP450 Enzymes: Afatinib is not an inhibitor or an inducer of CYP450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, and 3A4) in cultured primary human hepatocytes."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Diarrhea [see Warnings and Precautions (5.1) ] Bullous and Exfoliative Skin Disorders [see Warnings and Precautions (5.2) ] Interstitial Lung Disease [see Warnings and Precautions (5.3) ] Hepatic Toxicity [see Warnings and Precautions (5.4) ] Gastrointestinal Perforation [see Warnings and Precautions (5.5) ] Keratitis [see Warnings and Precautions (5.6) ] Most common adverse reactions (≥20%) were diarrhea, rash/acneiform dermatitis, stomatitis, paronychia, dry skin, decreased appetite, nausea, vomiting, pruritus ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in the Warnings and Precautions section reflect exposure to GILOTRIF for clinically significant adverse reactions in 4257 patients enrolled in LUX-Lung 3 (n=229) and LUX-Lung 8 (n=392), and 3636 patients with cancer enrolled in 42 studies of GILOTRIF administered alone or in combination with other anti-neoplastic drugs at GILOTRIF doses ranging from 10-70 mg daily or at doses 10-160 mg in other regimens. The mean exposure was 5.5 months. The population included patients with various cancers, the most common of which were NSCLC, breast, colorectal, brain, and head and neck. The data described below reflect exposure to GILOTRIF as a single agent in LUX-Lung 3, a randomized, active-controlled trial conducted in patients with EGFR mutation-positive, metastatic NSCLC, and in LUX-Lung 8, a randomized, active-controlled trial in patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy. EGFR Mutation-Positive Metastatic NSCLC The safety of GILOTRIF was evaluated in 229 EGFR-tyrosine kinase inhibitor-naïve patients with EGFR mutation-positive, metastatic non-squamous NSCLC enrolled in a randomized (2:1), multicenter, open-label trial (LUX-Lung 3). Patients received either GILOTRIF 40 mg daily until documented disease progression or intolerance to the therapy or pemetrexed 500 mg/m² followed after 30 minutes by cisplatin 75 mg/m² every three weeks for a maximum of six treatment courses. The median exposure was 11 months for patients treated with GILOTRIF and 3.4 months for patients treated with pemetrexed/cisplatin. The overall trial population had a median age of 61 years; 61% of patients in the GILOTRIF arm and 60% of patients in the pemetrexed/cisplatin arm were younger than 65 years. A total of 64% of patients on GILOTRIF and 67% of pemetrexed/cisplatin patients were female. More than two-thirds of patients were from Asia (GILOTRIF 70%; pemetrexed/cisplatin 72%). Serious adverse reactions were reported in 29% of patients treated with GILOTRIF. The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each). Fatal adverse reactions in GILOTRIF-treated patients in LUX-Lung 3 included pulmonary toxicity/ILD-like adverse reactions (1.3%), sepsis (0.43%), and pneumonia (0.43%). Dose reductions due to adverse reactions were required in 57% of GILOTRIF-treated patients. The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%). Discontinuation of therapy in GILOTRIF-treated patients for adverse reactions was 14.0%. The most frequent adverse reactions that led to discontinuation in GILOTRIF-treated patients were diarrhea (1.3%), ILD (0.9%), and paronychia (0.9%). Clinical trials of GILOTRIF excluded patients with an abnormal left ventricular ejection fraction (LVEF), i.e., below the institutional lower limit of normal. In LUX-Lung 3, all patients were evaluated for LVEF at screening and every 9 weeks thereafter in the GILOTRIF-treated group and as needed in the pemetrexed/cisplatin group. More GILOTRIF-treated patients (2.2%; n=5) experienced ventricular dysfunction (defined as diastolic dysfunction, left ventricular dysfunction, or ventricular dilation; all 40 mg: light blue, film-coated, round, biconvex, bevel-edged tablets debossed with "T40" on one side and the Boehringer Ingelheim company symbol on the other side. Unit of use bottles of 30 NDC: 0597-0138-30","
30 mg: dark blue, film-coated, round, biconvex, bevel-edged tablets debossed with "T30" on one side and the Boehringer Ingelheim company symbol on the other side.
Unit of use bottles of 30 NDC: 0597-0137-30
","
20 mg: white to slightly yellowish, film-coated, round, biconvex, bevel-edged tablets debossed with "T20" on one side and the Boehringer Ingelheim company symbol on the other side.
Unit of use bottles of 30NDC: 0597-0141-30
"],"mechanism_of_action":["12.1 Mechanism of Action Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the absence of ligand binding, and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those occurring in exons constituting the kinase domain of EGFR that lead to increased receptor activation and where efficacy is predicted by 1) clinically meaningful tumor shrinkage with the recommended dose of afatinib and/or 2) inhibition of cellular proliferation or EGFR tyrosine kinase phosphorylation at concentrations of afatinib sustainable at the recommended dosage according to validated methods. The most commonly found of these mutations are exon 21 L858R substitutions and exon 19 deletions. Afatinib demonstrated inhibition of autophosphorylation and/or in vitro proliferation of cell lines expressing wild-type EGFR and in those expressing selected EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common non-resistant mutations, at afatinib concentrations achieved in patients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2. Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors either overexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model."],"storage_and_handling":["Storage Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense medication in the original container to protect from exposure to high humidity and light."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the absence of ligand binding, and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those occurring in exons constituting the kinase domain of EGFR that lead to increased receptor activation and where efficacy is predicted by 1) clinically meaningful tumor shrinkage with the recommended dose of afatinib and/or 2) inhibition of cellular proliferation or EGFR tyrosine kinase phosphorylation at concentrations of afatinib sustainable at the recommended dosage according to validated methods. The most commonly found of these mutations are exon 21 L858R substitutions and exon 19 deletions. Afatinib demonstrated inhibition of autophosphorylation and/or in vitro proliferation of cell lines expressing wild-type EGFR and in those expressing selected EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common non-resistant mutations, at afatinib concentrations achieved in patients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2. Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors either overexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of multiple doses of GILOTRIF (50 mg once daily) on the QTc interval was evaluated in an open-label, single-arm study in patients with relapsed or refractory solid tumors. No large changes in the mean QTc interval (i.e., >20 ms) were detected in the study. 12.3 Pharmacokinetics Absorption Following oral administration of GILOTRIF tablets, time to peak afatinib plasma concentrations (T max ) is 2 to 5 hours. Maximum concentration (C max ) and area under the concentration-time curve from time zero to infinity (AUC 0-INF ) values increased slightly more than dose proportional in the range of 20 to 50 mg. The geometric mean relative bioavailability of 20 mg GILOTRIF tablets was 92% as compared to an oral solution. Steady-state plasma concentrations are achieved within 8 days of repeat dosing of GILOTRIF resulting in an accumulation of 2.8-fold for AUC and 2.1-fold for C max . Effect of Food A high-fat meal decreased C max by 50% and AUC 0-INF by 39% relative to the fasted condition [see Dosage and Administration (2.2) ] . Distribution In vitro binding of afatinib to human plasma proteins is approximately 95%. Elimination The elimination half-life of afatinib is 37 hours after repeat dosing in cancer patients. Metabolism Covalent adducts to proteins are the major circulating metabolites of afatinib and enzymatic metabolism of afatinib is minimal. The metabolites formed by CYP450-dependent reactions were approximately 9% of the total metabolic turnover in sandwich-cultured human hepatocytes. Approximately 2% of the afatinib dose was metabolized by FMO3; the CYP3A4-dependent N-demethylation was not detected. Excretion In humans, excretion of afatinib is primarily via the feces (85%) with 4% recovered in the urine following a single oral dose of [ 14 C]-labeled afatinib solution. The parent compound accounted for 88% of the recovered dose. Specific Populations Based on the population pharmacokinetic analysis, weight, gender, age, and race do not have a clinically important effect on exposure of afatinib. Patients with Renal Impairment A pharmacokinetic study was conducted in 14 subjects with normal (eGFR ≥90 mL/min/1.73 m 2 ) renal function, 8 subjects with moderate (eGFR 30 to 59 mL/min/1.73 m 2 ) and 8 subjects with severe (eGFR 15 to 29 mL/min/1.73 m 2 ) renal impairment. All subjects received a single 40 mg oral dose of GILOTRIF. The geometric mean AUC INF for afatinib was 50% higher in subjects with severe renal impairment and was 22% higher in subjects with moderate renal impairment as compared to subjects with normal renal function. Geometric mean C max was 22% higher in subjects with severe renal impairment and was comparable in subjects with moderate renal impairment to subjects with normal renal function [see Dosage and Administration (2.4) , Use in Specific Populations (8.6) ] . GILOTRIF has not been studied in patients with eGFR <15 mL/min/1.73 m 2 or on dialysis. Patients with Hepatic Impairment Mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment had no influence on the afatinib exposure following a single dose of GILOTRIF. Subjects with severe (Child Pugh C) hepatic impairment have not been studied [see Use in Specific Populations (8.7) ] . Drug Interactions Studies Clincial Studies Effect of P-gp Inhibitors and Inducers on Afatinib: The effect of ritonavir dosing time relative to a single oral dose of GILOTRIF was evaluated in healthy subjects taking 40 mg of GILOTRIF alone as compared to those after ritonavir (200 mg twice daily for 3 days) co-administration at 6 hours after GILOTRIF administration. The relative bioavailability for AUC 0-INF and C max of afatinib was 119% and 104% when co-administered with ritonavir, and 111% and 105% when ritonavir was administered 6 hours after taking GILOTRIF. In another study, when ritonavir (200 mg twice daily for 3 days) was administered 1 hour before a 20 mg single dose of GILOTRIF, exposure to afatinib increased by 48% for AUC 0-INF and 39% for C max [see Drug Interactions (7) ]. Pre-treatment with a potent inducer of P-gp, rifampicin (600 mg once daily for 7 days) decreased the plasma exposure to afatinib by 34% (AUC 0-INF ) and 22% (C max ) [see Drug Interactions (7) ] . In Vitro Studies Effect of Afatinib on P-gp: Based on in vitro data, afatinib is an inhibitor of P-gp. Interaction of Afatinib with BCRP: Based on in vitro data, afatinib is a substrate and an inhibitor of the transporter BCRP. Effect of Afatinib on CYP450 Enzymes: Afatinib is not an inhibitor or an inducer of CYP450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, and 3A4) in cultured primary human hepatocytes."],"indications_and_usage":["1 INDICATIONS AND USAGE GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ( 1.1 ) Limitations of Use : Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations ( 1.1 ) Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy ( 1.2 ) 1.1 EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) , Clinical Studies (14.1) ]. Limitations of Use : The safety and efficacy of GILOTRIF have not been established in patients whose tumors have resistant EGFR mutations [see Clinical Studies (14.1) ]. 1.2 Previously Treated, Metastatic Squamous NSCLC GILOTRIF is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy ."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Diarrhea : Diarrhea may result in dehydration and renal failure. Withhold GILOTRIF for severe and prolonged diarrhea not responsive to anti-diarrheal agents. ( 2.3 , 5.1 ) Bullous and exfoliative skin disorders : Severe bullous, blistering, and exfoliating lesions occurred in 0.2% of patients. Discontinue for life-threatening cutaneous reactions. Withhold GILOTRIF for severe and prolonged cutaneous reactions. ( 2.3 , 5.2 ) Interstitial lung disease (ILD) : Occurs in 1.6% of patients. Withhold GILOTRIF for acute onset or worsening of pulmonary symptoms. Discontinue GILOTRIF if ILD is diagnosed. ( 2.3 , 5.3 ) Hepatic toxicity : Fatal hepatic impairment occurs in 0.2% of patients. Monitor with periodic liver testing. Withhold or discontinue GILOTRIF for severe or worsening liver tests. ( 2.3 , 5.4 ) Gastrointestinal perforation : Occurs in 0.2% of patients. Permanently discontinue GILOTRIF in patients who develop gastrointestinal perforation. ( 2.3 , 5.5 ) Keratitis : Occurs in 0.7% of patients. Withhold GILOTRIF for keratitis evaluation. Withhold or discontinue GILOTRIF for confirmed ulcerative keratitis. ( 2.3 , 5.6 ) Embryo-fetal toxicity : Can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to the fetus and to use effective contraception. ( 5.7 ) 5.1 Diarrhea Diarrhea has resulted in dehydration with or without renal impairment across the clinical experience; some cases were fatal. Grade 3-4 diarrhea occurred in 697 (16%) of the 4257 patients who received GILOTRIF across 44 clinical trials. In LUX-Lung 3, diarrhea occurred in 96% of patients treated with GILOTRIF (n=229), of which 15% were Grade 3 in severity and occurred within the first 6 weeks . Renal impairment as a consequence of diarrhea occurred in 6% of patients treated with GILOTRIF, of which 1.3% were Grade 3. In LUX-Lung 8, diarrhea occurred in 75% of patients treated with GILOTRIF (n=392), of which 10% were Grade 3 in severity and 0.8% were Grade 4 in severity . Renal impairment as a consequence of diarrhea occurred in 7% of patients treated with GILOTRIF, of which 2% were Grade 3 [see Adverse Reactions (6.1) ]. For patients who develop prolonged Grade 2 diarrhea lasting more than 48 hours or greater than or equal to Grade 3 diarrhea, withhold GILOTRIF until diarrhea resolves to Grade 1 or less and resume GILOTRIF with appropriate dose reduction [see Dosage and Administration (2.3) ]. Provide patients with an anti-diarrheal agent (e.g., loperamide) for self-administration at the onset of diarrhea and instruct patients to continue anti-diarrheal therapy until loose bowel movements cease for 12 hours. 5.2 Bullous and Exfoliative Skin Disorders Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating skin lesions, occurred in 0.2% of the 4257 patients who received GILOTRIF across clinical trials . In LUX-Lung 3, the overall incidence of cutaneous reactions consisting of rash, erythema, and acneiform rash was 90%, and the incidence of Grade 3 cutaneous reactions was 16%. In addition, the incidence of Grade 1-3 palmar-plantar erythrodysesthesia syndrome was 7%. In LUX-Lung 8, the overall incidence of cutaneous reactions consisting of rash, erythema, and acneiform rash was 70%, and the incidence of Grade 3 cutaneous reactions was 7%. In addition, the incidence of Grade 1-3 palmar-plantar erythrodysesthesia syndrome was 1.5% [see Adverse Reactions (6.1) ] . Discontinue GILOTRIF in patients who develop life-threatening bullous, blistering, or exfoliating skin lesions . For patients who develop prolonged Grade 2 cutaneous adverse reactions lasting more than 7 days, intolerable Grade 2 cutaneous reactions, or Grade 3 cutaneous reactions, withhold GILOTRIF until the adverse reaction resolves to Grade 1 or less and resume GILOTRIF with appropriate dose reduction [see Dosage and Administration (2.3) ] . Postmarketing cases consistent with toxic epidermal necrolysis (TEN) and Stevens Johnson syndrome (SJS) have been reported in patients receiving GILOTRIF. The cases of TEN and SJS bullous skin reactions result from a distinct and separate mechanism of toxicity than the bullous skin lesions secondary to the pharmacologic action of the drug on the epidermal growth factor receptor. Discontinue GILOTRIF if TEN or SJS is suspected [see Dosage and Administration (2.3) ]. 5.3 Interstitial Lung Disease Interstitial lung disease or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.6% of the 4257 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal. The incidence of ILD appeared to be higher in Asian patients (2.3%; 38/1657) as compared to Whites (1.0%; 23/2241). In LUX-Lung 3, the incidence of Grade ≥3 ILD was 1.3% and resulted in death in 1% of GILOTRIF-treated patients. In LUX-Lung 8, the incidence of Grade ≥3 ILD was 0.9% and resulted in death in 0.8% of GILOTRIF-treated patients. Withhold GILOTRIF during evaluation of patients with suspected ILD and discontinue GILOTRIF in patients with confirmed ILD [see Dosage and Administration (2.3) ] . 5.4 Hepatic Toxicity In 4257 patients who received GILOTRIF across clinical trials, 9.7% had liver test abnormalities, of which 0.2% were fatal. In LUX-Lung 3, liver test abnormalities of any grade occurred in 17.5% of the patients treated with GILOTRIF, of which 3.5% had Grade 3-4 liver test abnormalities. In LUX-Lung 8, liver test abnormalities of any grade occurred in 6% of the patients treated with GILOTRIF, of which 0.2% had Grade 3-4 liver test abnormalities. Obtain periodic liver testing in patients during treatment with GILOTRIF. Withhold GILOTRIF in patients who develop worsening of liver function [see Dosage and Administration (2.3) ] . In patients who develop severe hepatic impairment while taking GILOTRIF, discontinue treatment. 5.5 Gastrointestinal Perforation Gastrointestinal perforation, including fatal cases, has occurred with GILOTRIF. Gastrointestinal perforation has been reported in 0.2% of patients treated with GILOTRIF among 3213 patients across 17 randomized controlled clinical trials. Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. Permanently discontinue GILOTRIF in patients who develop gastrointestinal perforation [see Dosage and Administration (2.3) ] . 5.6 Keratitis Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.7% of patients treated with GILOTRIF among 4257 patients across clinical trials, of which 0.05% of patients experienced Grade 3 keratitis. Keratitis was reported in 2.2% patients in LUX-Lung 3, with Grade 3 in 0.4%. In LUX-Lung 8, keratitis was reported in 0.3% patients; there were no patients with ≥Grade 3 keratitis. Withhold GILOTRIF during evaluation of patients with suspected keratitis, and if diagnosis of ulcerative keratitis is confirmed, interrupt or discontinue GILOTRIF [see Dosage and Administration (2.3) ] . If keratitis is diagnosed, the benefits and risks of continuing treatment should be carefully considered. GILOTRIF should be used with caution in patients with a history of keratitis, ulcerative keratitis, or severe dry eye [see Adverse Reactions (6.1) ] . Contact lens use is also a risk factor for keratitis and ulceration. 5.7 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, GILOTRIF can cause fetal harm when administered to a pregnant woman. Administration of afatinib to pregnant rabbits during organogenesis at exposures approximately 0.2 times the exposure in humans at the recommended dose of 40 mg daily resulted in embryotoxicity and, in rabbits showing maternal toxicity, increased abortions at late gestational stages. Advise pregnant women and females of reproductive potential of the potential risk to a fetus . Advise females of reproductive potential to use effective contraception during treatment and for at least 2 weeks after the last dose of GILOTRIF [see Use in Specific Populations (8.1 , 8.3) ]."],"clinical_studies_table":["
Table 5 Efficacy Results in LUX-Lung 3
GILOTRIF (N=230)Pemetrexed/Cisplatin (N=115)
*Stratified by EGFR mutation status and race.
HR=hazard ratio; CR=complete response; PR=partial response
Progression-Free Survival by IRC
Number of Deaths or Progressions, N (%)152 (66.1%)69 (60.0%)
Median Progression-Free Survival (months)11.16.9
95% CI(9.6, 13.6)(5.4, 8.2)
HR (95% CI)0.58 (0.43, 0.78)
Stratified Log-Rank Test p-value*<0.001
Overall Survival
Number of Deaths, N (%)140 (60.9%)73 (63.5%)
Median Overall Survival (months)28.228.2
95% CI(24.6, 33.6)(20.7, 33.2)
HR (95% CI)0.88 (0.66, 1.17)
Stratified Log-Rank Test p-value*0.39
Overall Response Rate (CR + PR) by IRC
N (%)116 (50.4%)22 (19.1%)
Response Duration
Median (months)12.56.7
","
Table 6 IRC-Assessed Responses in Patients with NSCLC Harboring EGFR Mutations G719X, L861Q, and/or S768I from LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
EGFR MutationNumber of GILOTRIF Treated Patients (N=32)Number of Confirmed Responses (N=21)Duration of Response (months) (N=21)
+ response ongoing at time of censoring
S768I1137.3
S768I and G719X544.1, 13.2, 15.2, 29.5+
S768I and L858R2134.5+
G719X865.7+, 8.1, 9.6, 23.5+, 25.2, 31.8+
G719X and L861Q322.8+, 6.8
L861Q1272.8, 4.0, 4.1, 8.3+, 12.9, 15.2, 20.6
L861Q and Del 1910NA
","
Table 7 Efficacy Results in LUX-Lung 8
GILOTRIFErlotinib
*Log-rank test stratified by region.
HR=hazard ratio
Overall Survival
N=398N=397
Number of Deaths, N (%)307 (77%)325 (82%)
Median overall survival (months)7.96.8
95% CI(7.2, 8.7)(5.9, 7.8)
HR (95% CI)0.81 (0.69, 0.95)
p-value*0.008
Progression-Free Survival (PFS) by IRC
N=335N=334
Number of Events, N (%)202 (60%)212 (64%)
Median PFS (months)2.41.9
95% CI(1.9, 2.9)(1.9, 2.2)
HR (95% CI)0.82 (0.68, 0.998)
p-value*0.0427
Overall Response Rate (ORR) by IRC
N=335N=334
ORR3%2%
(95% CI)(1.7, 5.8)(0.8, 4.3)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with afatinib. A marginal response to afatinib was observed in a single tester strain of a bacterial (Ames) mutagenicity assay. No mutagenic or genotoxic potential was identified in an in vitro chromosomal aberration test at non-cytotoxic concentrations as well as in the in vivo bone marrow micronucleus assay, the in vivo Comet assay, and an in vivo 4-week oral mutation study in the Muta ™ Mouse. In a dedicated fertility study, male and female rats received afatinib daily by oral administration at doses of 4, 6, or 8 mg/kg. In males at doses of 6 mg/kg (approximately equal to the exposure by AUC in patients at the recommended human dose of 40 mg daily) or greater, there was an increase in the incidence of low or no sperm count, though overall fertility was not affected; decreases in sperm count were supported by findings of increased apoptosis in the testes and atrophy in the seminal vesicles and the prostate in general toxicology studies. In females at the high dose of 8 mg/kg (approximately 0.63 times the exposure by AUC in patients at the recommended human dose of 40 mg daily), there was a mild decrease in the number of corpora lutea along with a mild increase in post-implantation loss due to early resorptions. In a 4-week general toxicology study, female rats had decreases in ovarian weights at all dose levels; organ weight had not fully recovered by the end of a 2-week recovery period."],"adverse_reactions_table":["
Table 1 Adverse Reactions Reported in ≥10% of GILOTRIF-Treated Patients in LUX-Lung 3*
Adverse ReactionGILOTRIF n=229Pemetrexed/Cisplatin n=111
All Grades (%)Grade 3† (%)All Grades (%)Grade 3† (%)
*NCI CTCAE v 3.0
†None of the adverse reactions in this table except stomatitis (one patient on GILOTRIF [0.4%]) were Grade 4 in severity.
1Includes stomatitis, aphthous stomatitis, mucosal inflammation, mouth ulceration, oral mucosa erosion, mucosal erosion, mucosal ulceration
2Includes acne, acne pustular, dermatitis, acneiform dermatitis, dermatosis, drug eruption, erythema, exfoliative rash, folliculitis, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculo-papular, rash pruritic, rash pustular, skin disorder, skin erosion, skin exfoliation, skin fissures, skin lesion, skin reaction, skin toxicity, skin ulcer
3Includes paronychia, nail infection, nail bed infection
Gastrointestinal disorders
Diarrhea9615232
Stomatitis1719151
Cheilitis12010
Skin and subcutaneous tissue disorders
Rash/acneiform dermatitis29016110
Pruritus21010
Dry skin31020
Infections
Paronychia3581100
Cystitis13150
Respiratory, thoracic and mediastinal disorders
Epistaxis17021
Rhinorrhea11060
Investigations
Weight decreased171141
General disorders and administration site conditions
Pyrexia12060
Eye disorders
Conjunctivitis11030
","
Table 2 Laboratory Abnormalities Occurring in ≥10% of GILOTRIF Arm and at ≥2% Higher Incidence than in Chemotherapy Arm in LUX-Lung 3*
Laboratory AbnormalityGILOTRIF n=229Pemetrexed/Cisplatin n=111
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
*NCI CTCAE v 3.0
Increased alanine aminotransferase (ALT)542271
Increased alkaline phosphate513461
Decreased creatinine clearance492471
Increased aspartate aminotransferase (AST)463221
Decreased lymphocytes3893214
Decreased potassium308113
Increased bilirubin16180
","
Table 3 Adverse Reactions Reported in ≥10% of GILOTRIF-Treated Patients in LUX-Lung 8*
Adverse ReactionGILOTRIF n=392Erlotinib n=395
All Grades (%)Grade 3-4 (%)All Grades (%)Grade 3-4 (%)
*NCI CTCAE v 3.0
1Includes stomatitis, aphthous stomatitis, mucosal inflammation, mouth ulceration, oral mucosa erosion, mucosal erosion, mucosal ulceration
2Includes acne, dermatitis, acneiform dermatitis, eczema, erythema, exfoliative rash, folliculitis, rash, rash generalized, rash macular, rash maculo-papular, rash pruritic, rash pustular, skin exfoliation, skin fissures, skin lesion, skin reaction, skin toxicity, skin ulcer
3Includes paronychia, nail infection, nail bed infection
Gastrointestinal disorders
Diarrhea7511413
Stomatitis1304111
Nausea212161
Vomiting131101
Skin and subcutaneous tissue disorders
Rash/acneiform dermatitis27077011
Pruritus100130
Metabolism and nutrition disorders
Decreased appetite253262
Infections
Paronychia311150
","
Table 4 Laboratory Abnormalities Occurring in ≥10% of GILOTRIF Arm and at ≥2% Higher Incidence than in Erlotinib Arm in LUX-Lung 8*
Laboratory AbnormalityGILOTRIF n=392Erlotinib n=395
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
*NCI CTCAE v 3.0
Increased alkaline phosphate342310
Decreased white blood cell count12181
Decreased potassium11181
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Diarrhea Advise patients that diarrhea occurs in nearly all patients who receive GILOTRIF. Inform patients that diarrhea may result in dehydration and renal impairment if not treated. Advise patients to notify their physician if diarrhea develops and to seek medical attention promptly for severe or persistent diarrhea [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. Bullous and Exfoliative Skin Disorders Advise patients to minimize sun exposure with protective clothing and use of sunscreen while taking GILOTRIF [see Warnings and Precautions (5.2) ]. Interstitial Lung Disease Advise patients to immediately report any new or worsening lung symptoms, or any combination of the following symptoms: trouble breathing or shortness of breath, cough, fever [see Warnings and Precautions (5.3) ]. Hepatic Toxicity Advise patients that they will need to undergo liver function monitoring periodically. Advise patients to immediately report any symptoms of a liver problem [e.g., skin or the whites of eyes turn yellow, urine turns dark or brown (tea colored), pain on the right side of stomach, bleeds or bruises more easily than normal, lethargy] [see Warnings and Precautions (5.4) ]. Gastrointestinal Perforation Advise patients that GILOTRIF can increase the risk of gastrointestinal perforation and to seek immediate medical attention for severe abdominal pain [see Warnings and Precautions (5.5) ] . Keratitis Advise patients to immediately report eye problems (e.g., eye pain, swelling, redness, blurred vision, or other vision changes) [see Warnings and Precautions (5.6) ]. Left Ventricular Dysfunction Advise patients to contact a healthcare professional immediately for any of the following: new onset or worsening shortness of breath or exercise intolerance, cough, fatigue, swelling of the ankles/legs, palpitations, or sudden weight gain [see Dosage and Administration (2.3) and Adverse Reactions (6.1) ]. Instructions for Taking GILOTRIF Advise patients to take GILOTRIF on an empty stomach at least 1 hour before or 2 hours after eating [see Dosage and Administration (2.2) ]. Advise patients not to take a missed dose within 12 hours of the next dose. Embryo-Fetal Toxicity Advise pregnant women and females of reproductive potential that GILOTRIF can result in fetal harm. Advise female patients to contact their healthcare provider with a known or suspected pregnancy . Advise females of reproductive potential to use effective contraception during treatment with GILOTRIF and for at least 2 weeks after the last dose of GILOTRIF [see Use in Specific Populations (8.1 , 8.3) ]. Lactation Advise women not to breastfeed during treatment with GILOTRIF and for 2 weeks after the last dose of GILOTRIF [see Use in Specific Populations (8.2) ]. Infertility Advise females and males of reproductive potential of the potential for reduced fertility from GILOTRIF [see Use in Specific Populations (8.3) ] ."],"spl_unclassified_section":["Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA Licensed from: Boehringer Ingelheim International GmbH GILOTRIF is a registered trademark of and used under license from Boehringer Ingelheim International GmbH. The other brands listed are trademarks of their respective owners and are not trademarks of Boehringer Ingelheim Pharmaceuticals, Inc. Copyright © 2022 Boehringer Ingelheim International GmbH ALL RIGHTS RESERVED COL9594AD042022 SPL9596A"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended dosage : 40 mg orally once daily ( 2.2 ) Renal impairment : 30 mg orally once daily in patients with severe renal impairment ( 2.4 , 8.6 , 12.3 ) Instruct patients to take GILOTRIF at least 1 hour before or 2 hours after a meal ( 2.2 ) 2.1 Patient Selection for Non-Resistant EGFR Mutation-Positive Metastatic NSCLC Select patients for first-line treatment of metastatic NSCLC with GILOTRIF based on the presence of non-resistant EGFR mutations in tumor specimens [see Clinical Pharmacology (12.1) , Clinical Studies (14.1) ]. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics . 2.2 Recommended Dosage The recommended dosage of GILOTRIF is 40 mg orally once daily until disease progression or no longer tolerated by the patient. Take GILOTRIF at least 1 hour before or 2 hours after a meal. Do not take a missed dose within 12 hours of the next dose. 2.3 Dosage Modifications for Adverse Reactions Withhold GILOTRIF for: Grade* 3 or higher adverse reactions Diarrhea of Grade 2 persisting for 2 or more consecutive days while taking anti-diarrheal medication [see Warnings and Precautions (5.1) ] Cutaneous reactions of Grade 2 that are prolonged (lasting more than 7 days) or intolerable [see Warnings and Precautions (5.2) ] * National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v 3.0 Resume treatment when the adverse reaction fully resolves, returns to baseline, or improves to Grade 1. Reinstitute GILOTRIF at a reduced dose, i.e., 10 mg per day less than the dose at which the adverse reaction occurred. Permanently discontinue GILOTRIF for: Life-threatening bullous, blistering, or exfoliating skin lesions [see Warnings and Precautions (5.2) ] Confirmed interstitial lung disease (ILD) [see Warnings and Precautions (5.3) ] Severe drug-induced hepatic impairment [see Warnings and Precautions (5.4) ] Gastrointestinal perforation [see Warnings and Precautions (5.5) ] Persistent ulcerative keratitis [see Warnings and Precautions (5.6) ] Symptomatic left ventricular dysfunction [see Adverse Reactions (6.1) ] Severe or intolerable adverse reaction occurring at a dose of 20 mg per day 2.4 Dosage Modification for Pre-Existing Severe Renal Impairment The recommended dosage of GILOTRIF in patients with pre-existing severe renal impairment (estimated glomerular filtration rate [eGFR*] 15 to 29 mL/min /1.73 m 2 ) is 30 mg orally once daily [see Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ] . * Use the Modification of Diet in Renal Disease [MDRD] formula to estimate eGFR. 2.5 Dosage Modifications for Drug Interactions P-glycoprotein Inhibitors Reduce GILOTRIF daily dose by 10 mg if not tolerated for patients who require therapy with a P-glycoprotein (P-gp) inhibitor. Resume the previous dose after discontinuation of the P-gp inhibitor as tolerated [see Drug Interactions (7) , Clinical Pharmacology (12.3) ] . P-glycoprotein Inducers Increase GILOTRIF daily dose by 10 mg as tolerated for patients who require chronic therapy with a P-gp inducer. Resume the previous dose 2 to 3 days after discontinuation of the P-gp inducer [see Drug Interactions (7) , Clinical Pharmacology (12.3) ]."],"spl_product_data_elements":["Gilotrif afatinib AFATINIB AFATINIB Slightly yellowish T20 Gilotrif afatinib AFATINIB AFATINIB Dark Blue T30 Gilotrif afatinib AFATINIB AFATINIB Light Blue T40"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS GILOTRIF is available as: 40 mg tablets: light blue, film-coated, round, biconvex, bevel-edged tablets debossed with \"T40\" on one side and the Boehringer Ingelheim company symbol on the other side. 30 mg tablets: dark blue, film-coated, round, biconvex, bevel-edged tablets debossed with \"T30\" on one side and the Boehringer Ingelheim company symbol on the other side. 20 mg tablets: white to slightly yellowish, film-coated, round, biconvex, bevel-edged tablets debossed with \"T20\" on one side and the Boehringer Ingelheim company symbol on the other side. Tablets: 40 mg, 30 mg, and 20 mg ( 3 )"],"spl_patient_package_insert":["Patient Information GILOTRIF ® (JEE-loh-trif) (afatinib tablets) This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: April 2022 What is GILOTRIF? GILOTRIF is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that: has certain (non-resistant) abnormal epidermal growth factor receptor (EGFR) gene(s). Your healthcare provider will perform a test to make sure that GILOTRIF is right for you. has spread to other parts of the body (metastatic), and has not been previously treated for metastatic lung cancer It is not known if GILOTRIF is safe and effective in treating people with lung cancer that has resistant abnormal EGFR genes. or is used to treat people with squamous cell lung cancer that: has spread to other parts of the body, and has been previously treated with chemotherapy that contains platinum. It is not known if GILOTRIF is safe and effective in children. Before you take GILOTRIF, tell your healthcare provider about all of your medical conditions, including if you: have kidney or liver problems have lung or breathing problems other than lung cancer have a history of an ulcer, a tear (perforation) in your stomach or intestine, or diverticular disease (inflammation) in parts of your large intestine. See \" What are the possible side effects of GILOTRIF? \" have a history of severe dry eye or any other eye problems. Tell your healthcare provider if you wear contact lenses. have heart problems are pregnant or plan to become pregnant. GILOTRIF can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with GILOTRIF and for at least 2 weeks after your last dose of GILOTRIF. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with GILOTRIF. are breastfeeding or plan to breastfeed. It is not known if GILOTRIF passes into your breast milk. Do not breastfeed during treatment with GILOTRIF and for 2 weeks after your last dose of GILOTRIF. Talk to your healthcare provider about the best way to feed your baby if you take GILOTRIF. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. GILOTRIF may affect the way other medicines work, and other medicines may affect the way GILOTRIF works. Taking certain medicines with GILOTRIF may increase your risk of developing a tear (perforation) in your stomach or intestine. See \" What are the possible side effects of GILOTRIF? \" Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. How should I take GILOTRIF? Take GILOTRIF exactly as your healthcare provider tells you to take it. Your healthcare provider will tell you how many GILOTRIF tablets to take and when to take them. Do not change your dose or stop GILOTRIF unless your healthcare provider tells you to. Take GILOTRIF on an empty stomach at least 1 hour before a meal or 2 hours after a meal. If you miss a dose of GILOTRIF, take it as soon as you remember. If it is within 12 hours of your next dose, skip the dose and just take your next dose at your regular time. Do not take 2 doses of GILOTRIF at the same time. If you take too much GILOTRIF, call your healthcare provider or go to the nearest hospital emergency room right away. What should I avoid while taking GILOTRIF? Limit your time in the sun. GILOTRIF can make your skin sensitive to sunlight. You could get or have worsening rash or acne. You could get a severe sunburn. Use sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight during treatment with GILOTRIF. What are the possible side effects of GILOTRIF? GILOTRIF may cause serious side effects, including: diarrhea. Diarrhea is common with GILOTRIF and may sometimes be severe. Severe diarrhea can cause loss of too much body fluid (dehydration) and kidney problems that can sometimes lead to death. During your treatment with GILOTRIF, your healthcare provider should prescribe medicines to treat diarrhea. Take this medicine exactly as your healthcare provider tells you to. Tell your healthcare provider if you have diarrhea. Get medical attention right away if your diarrhea does not go away or becomes severe. skin reactions. GILOTRIF can cause redness, rash, and acne. It is important to get treatment for skin reactions as soon as you notice them. Take medicines to help skin reactions exactly as your healthcare provider tells you to. Get medical attention right away if you develop severe skin reactions such as peeling or blistering of the skin, or blisters in your mouth. lung or breathing problems. GILOTRIF may cause inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung problems, or any combination of the following symptoms: trouble breathing or shortness of breath, cough, or fever. liver problems. GILOTRIF can cause liver problems that can sometimes lead to death. Tell your healthcare provider right away if you have any symptoms of a liver problem which may include: yellowing of your skin or the white part of your eyes (jaundice) dark or brown (tea colored) urine pain on the upper right side of your stomach area (abdomen) bleeding or bruising more easily than normal feeling very tired Your healthcare provider will do blood tests to check your liver function during your treatment with GILOTRIF. tear (perforation) in your stomach or intestine. Tears in your stomach or intestine can happen with GILOTRIF and can sometimes lead to death. Your risk of developing a tear in your stomach or intestine may be increased if you: take certain medicines with GILOTRIF including: corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain other medicines. have a history of stomach or intestinal ulcers, or if you have had diverticular disease (inflammation in parts of the large intestine). Get medical help right away if you develop severe stomach-area (abdomen) pain during treatment with GILOTRIF. eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include: eye pain, swelling, redness, or tearing blurred vision sensitivity to light other changes in your vision heart problems. Tell your healthcare provider right away if you have symptoms of a heart problem which may include: new or worsening shortness of breath while at rest or with activity cough tiredness swelling of your ankles, feet, or legs feeling that your heart is pounding or racing (palpitations) sudden weight gain Your healthcare provider may change your dose, temporarily stop or permanently stop treatment with GILOTRIF if you have certain side effects. The most common side effects of GILOTRIF include: diarrhea rash acne mouth sores nail inflammation dry skin decreased appetite nausea vomiting itching GILOTRIF may cause decreased fertility in females and males. This may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of GILOTRIF. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store GILOTRIF? Store GILOTRIF at room temperature between 68°F to 77°F (20°C to 25°C). Keep GILOTRIF in the original container and keep the container tightly closed. Keep GILOTRIF away from moisture and light. Safely throw away (discard) any GILOTRIF that is out of date or no longer needed. Keep GILOTRIF and all medicines out of the reach of children. General information about GILOTRIF Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use GILOTRIF for a condition for which it was not prescribed. Do not give GILOTRIF to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about GILOTRIF that is written for health professionals. What are the ingredients in GILOTRIF? Active ingredient: afatinib Inactive ingredients: Tablet Core: lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate. Tablet Coating: hypromellose, polyethylene glycol, titanium dioxide, talc, polysorbate 80, FD&C Blue No. 2 (40 mg and 30 mg tablets only). Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA Licensed from: Boehringer Ingelheim International GmbH GILOTRIF is a registered trademark of and used under license from Boehringer Ingelheim International GmbH. Copyright © 2022 Boehringer Ingelheim International GmbH ALL RIGHTS RESERVED COL9594AD042022 For more information about GILOTRIF, including current prescribing information, go to www.gilotrif.com , scan the code, or call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257. Figure"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Advise women not to breastfeed ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , GILOTRIF can cause fetal harm when administered to a pregnant woman. There are no available data on the use of GILOTRIF in pregnant women. Administration of afatinib to pregnant rabbits during organogenesis at exposures approximately 0.2 times the exposure in humans at the recommended dose of 40 mg daily resulted in embryotoxicity and, in rabbits showing maternal toxicity, increased abortions at late gestational stages (see Data ) . Advise a pregnant woman of the potential risk to a fetus . The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal development study in rabbits, administration of afatinib to pregnant animals at doses of 5 mg/kg (approximately 0.2 times the exposure by AUC at the recommended human dose of 40 mg daily) or greater during the period of organogenesis caused increased post-implantation loss, and in animals showing maternal toxicity, abortion at late gestational stages. In the same study, at the high dose level of 10 mg/kg (approximately 0.7 times the exposure by AUC at the recommended human dose of 40 mg daily), there were reduced fetal weights, and increases in the incidence of runts, as well as visceral and dermal variations. In an embryo-fetal development study in rats, there were skeletal alterations consisting of incomplete or delayed ossifications and reduced fetal weight at a dose of 16 mg/kg (approximately twice the exposure based on AUC at the recommended human dose of 40 mg daily). 8.2 Lactation Risk Summary There are no data on the presence of afatinib in human milk or its effects on the breastfed infant or on milk production. Afatinib was present in the milk of lactating rats (see Data ) . Because of the potential for serious adverse reactions in breastfed infants from GILOTRIF, advise women not to breastfeed during treatment with GILOTRIF and for 2 weeks after the final dose. Data Afatinib was present in the milk of lactating rats at concentrations 80 and 150 times higher than those found in plasma at 1 and 6 hours after administration. 8.3 Females and Males of Reproductive Potential Contraception Females GILOTRIF can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with GILOTRIF and for at least 2 weeks after the last dose of GILOTRIF [see Use in Specific Populations (8.1) , Clinical Pharmacology (12.3) ]. Infertility Based on results from an animal fertility study, GILOTRIF may reduce fertility in females and males of reproductive potential. It is not known if the effects on fertility are reversible [see Nonclinical Toxicology (13.1) ]. 8.4 Pediatric Use Safety and effectiveness of GILOTRIF in pediatric patients have not been established. The safety and efficacy of afatinib were assessed, but not established, in a single-arm, open-label, multicenter trial [NCT02372006] which included 37 pediatric patients 2 to <17 years of age with recurrent/refractory solid tumors with known ErbB pathway deregulation who received 80% of the adult dose per body surface area. No new safety signals were observed in pediatric patients in this trial. In these 37 patients, the pharmacokinetic parameters were within range of values in adults. 8.5 Geriatric Use LUX-Lung 3 did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In LUX-Lung 8, 53% of the 398 patients randomized to receive afatinib were 65 years of age or older and 11% were 75 years or older. In an exploratory subgroup analysis of LUX-Lung 8, the hazard ratio for overall survival (OS) in patients less than 65 years old was 0.68 (95% CI: 0.55, 0.85) and in patients 65 years or older was 0.95 (95% CI: 0.76, 1.19). No overall differences in safety were observed between patients 65 years and older and younger patients. 8.6 Renal Impairment Patients with severe renal impairment have a higher exposure to afatinib than patients with normal renal function. Administer GILOTRIF at a starting dose of 30 mg once daily in patients with severe renal impairment (eGFR 15 to 29 mL/min /1.73 m 2 as determined by Modification of Diet in Renal Disease formula) [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . Adjustments to the starting dose of GILOTRIF are not necessary in patients with mild or moderate renal impairment (eGFR 30 to 89 mL/min /1.73 m 2 ). GILOTRIF has not been studied in patients with eGFR <15 mL/min/1.73 m 2 or on dialysis. 8.7 Hepatic Impairment GILOTRIF has not been studied in patients with severe (Child Pugh C) hepatic impairment. Adjustments to the starting dose of GILOTRIF are not necessary in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment [see Clinical Pharmacology (12.3) ] . Closely monitor patients with severe hepatic impairment and adjust GILOTRIF dose if not tolerated."],"spl_patient_package_insert_table":["
Patient Information GILOTRIF® (JEE-loh-trif) (afatinib tablets)
This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: April 2022
What is GILOTRIF? GILOTRIF is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that:has certain (non-resistant) abnormal epidermal growth factor receptor (EGFR) gene(s). Your healthcare provider will perform a test to make sure that GILOTRIF is right for you.has spread to other parts of the body (metastatic), and has not been previously treated for metastatic lung cancerIt is not known if GILOTRIF is safe and effective in treating people with lung cancer that has resistant abnormal EGFR genes. or is used to treat people with squamous cell lung cancer that: has spread to other parts of the body, andhas been previously treated with chemotherapy that contains platinum.It is not known if GILOTRIF is safe and effective in children.
Before you take GILOTRIF, tell your healthcare provider about all of your medical conditions, including if you:have kidney or liver problemshave lung or breathing problems other than lung cancerhave a history of an ulcer, a tear (perforation) in your stomach or intestine, or diverticular disease (inflammation) in parts of your large intestine. See "What are the possible side effects of GILOTRIF?"have a history of severe dry eye or any other eye problems. Tell your healthcare provider if you wear contact lenses.have heart problemsare pregnant or plan to become pregnant. GILOTRIF can harm your unborn baby.Females who are able to become pregnant should use effective birth control during treatment with GILOTRIF and for at least 2 weeks after your last dose of GILOTRIF. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with GILOTRIF.are breastfeeding or plan to breastfeed. It is not known if GILOTRIF passes into your breast milk. Do not breastfeed during treatment with GILOTRIF and for 2 weeks after your last dose of GILOTRIF. Talk to your healthcare provider about the best way to feed your baby if you take GILOTRIF.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. GILOTRIF may affect the way other medicines work, and other medicines may affect the way GILOTRIF works. Taking certain medicines with GILOTRIF may increase your risk of developing a tear (perforation) in your stomach or intestine. See "What are the possible side effects of GILOTRIF?" Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
How should I take GILOTRIF?Take GILOTRIF exactly as your healthcare provider tells you to take it.Your healthcare provider will tell you how many GILOTRIF tablets to take and when to take them. Do not change your dose or stop GILOTRIF unless your healthcare provider tells you to.Take GILOTRIF on an empty stomach at least 1 hour before a meal or 2 hours after a meal.If you miss a dose of GILOTRIF, take it as soon as you remember. If it is within 12 hours of your next dose, skip the dose and just take your next dose at your regular time. Do not take 2 doses of GILOTRIF at the same time.If you take too much GILOTRIF, call your healthcare provider or go to the nearest hospital emergency room right away.
What should I avoid while taking GILOTRIF? Limit your time in the sun. GILOTRIF can make your skin sensitive to sunlight. You could get or have worsening rash or acne. You could get a severe sunburn. Use sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight during treatment with GILOTRIF.
What are the possible side effects of GILOTRIF? GILOTRIF may cause serious side effects, including:diarrhea. Diarrhea is common with GILOTRIF and may sometimes be severe. Severe diarrhea can cause loss of too much body fluid (dehydration) and kidney problems that can sometimes lead to death. During your treatment with GILOTRIF, your healthcare provider should prescribe medicines to treat diarrhea. Take this medicine exactly as your healthcare provider tells you to. Tell your healthcare provider if you have diarrhea. Get medical attention right away if your diarrhea does not go away or becomes severe.skin reactions. GILOTRIF can cause redness, rash, and acne. It is important to get treatment for skin reactions as soon as you notice them. Take medicines to help skin reactions exactly as your healthcare provider tells you to. Get medical attention right away if you develop severe skin reactions such as peeling or blistering of the skin, or blisters in your mouth.lung or breathing problems. GILOTRIF may cause inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung problems, or any combination of the following symptoms: trouble breathing or shortness of breath, cough, or fever.liver problems. GILOTRIF can cause liver problems that can sometimes lead to death. Tell your healthcare provider right away if you have any symptoms of a liver problem which may include:yellowing of your skin or the white part of your eyes (jaundice)dark or brown (tea colored) urinepain on the upper right side of your stomach area (abdomen)bleeding or bruising more easily than normalfeeling very tiredYour healthcare provider will do blood tests to check your liver function during your treatment with GILOTRIF. tear (perforation) in your stomach or intestine. Tears in your stomach or intestine can happen with GILOTRIF and can sometimes lead to death. Your risk of developing a tear in your stomach or intestine may be increased if you:take certain medicines with GILOTRIF including: corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain other medicines.have a history of stomach or intestinal ulcers, or if you have had diverticular disease (inflammation in parts of the large intestine).Get medical help right away if you develop severe stomach-area (abdomen) pain during treatment with GILOTRIF. eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include:
eye pain, swelling, redness, or tearingblurred vision sensitivity to lightother changes in your vision
heart problems. Tell your healthcare provider right away if you have symptoms of a heart problem which may include:
new or worsening shortness of breath while at rest or with activitycoughtirednessswelling of your ankles, feet, or legsfeeling that your heart is pounding or racing (palpitations)sudden weight gain
Your healthcare provider may change your dose, temporarily stop or permanently stop treatment with GILOTRIF if you have certain side effects. The most common side effects of GILOTRIF include:
diarrhearashacnemouth soresnail inflammationdry skindecreased appetitenauseavomitingitching
GILOTRIF may cause decreased fertility in females and males. This may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of GILOTRIF. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store GILOTRIF?Store GILOTRIF at room temperature between 68°F to 77°F (20°C to 25°C). Keep GILOTRIF in the original container and keep the container tightly closed.Keep GILOTRIF away from moisture and light.Safely throw away (discard) any GILOTRIF that is out of date or no longer needed.Keep GILOTRIF and all medicines out of the reach of children.
General information about GILOTRIF Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use GILOTRIF for a condition for which it was not prescribed. Do not give GILOTRIF to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about GILOTRIF that is written for health professionals.
What are the ingredients in GILOTRIF? Active ingredient: afatinib Inactive ingredients: Tablet Core: lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate. Tablet Coating: hypromellose, polyethylene glycol, titanium dioxide, talc, polysorbate 80, FD&C Blue No. 2 (40 mg and 30 mg tablets only).
Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA Licensed from: Boehringer Ingelheim International GmbH GILOTRIF is a registered trademark of and used under license from Boehringer Ingelheim International GmbH. Copyright © 2022 Boehringer Ingelheim International GmbH ALL RIGHTS RESERVED COL9594AD042022 For more information about GILOTRIF, including current prescribing information, go to www.gilotrif.com, scan the code, or call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257.
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Carton NDC 0597-0141-30 GILOTRIF ® (afatinib tablets) 20 mg* Attention: Dispense and Store Medication in the Original Container to Protect from Light and Humidity. Recommended Dosage: See Prescribing Information. 30 tablets Boehringer Ingelheim Rx only PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Carton","PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Carton NDC 0597-0137-30 GILOTRIF ® (afatinib tablets) 30 mg* Attention: Dispense and Store Medication in the Original Container to Protect from Light and Humidity. Recommended Dosage: See Prescribing Information. 30 tablets Boehringer Ingelheim Rx only PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Carton","PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Carton NDC 0597-0138-30 GILOTRIF ® (afatinib tablets) 40 mg* Attention: Dispense and Store Medication in the Original Container to Protect from Light and Humidity. Recommended Dosage: See Prescribing Information. 30 tablets Boehringer Ingelheim Rx only PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with afatinib. A marginal response to afatinib was observed in a single tester strain of a bacterial (Ames) mutagenicity assay. No mutagenic or genotoxic potential was identified in an in vitro chromosomal aberration test at non-cytotoxic concentrations as well as in the in vivo bone marrow micronucleus assay, the in vivo Comet assay, and an in vivo 4-week oral mutation study in the Muta ™ Mouse. In a dedicated fertility study, male and female rats received afatinib daily by oral administration at doses of 4, 6, or 8 mg/kg. In males at doses of 6 mg/kg (approximately equal to the exposure by AUC in patients at the recommended human dose of 40 mg daily) or greater, there was an increase in the incidence of low or no sperm count, though overall fertility was not affected; decreases in sperm count were supported by findings of increased apoptosis in the testes and atrophy in the seminal vesicles and the prostate in general toxicology studies. In females at the high dose of 8 mg/kg (approximately 0.63 times the exposure by AUC in patients at the recommended human dose of 40 mg daily), there was a mild decrease in the number of corpora lutea along with a mild increase in post-implantation loss due to early resorptions. In a 4-week general toxicology study, female rats had decreases in ovarian weights at all dose levels; organ weight had not fully recovered by the end of a 2-week recovery period."]},"tags":[{"label":"Kinase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Epidermal growth factor receptor","category":"target"},{"label":"EGFR","category":"gene"},{"label":"ERBB2","category":"gene"},{"label":"ERBB4","category":"gene"},{"label":"L01EB03","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","category":"indication"},{"label":"Boehringer Ingelheim","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protein Kinase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"2090 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"1671 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"866 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"514 reports"},{"date":"","signal":"STOMATITIS","source":"FDA FAERS","actionTaken":"483 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"476 reports"},{"date":"","signal":"DECREASED APPETITE","source":"FDA FAERS","actionTaken":"448 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"400 reports"},{"date":"","signal":"PARONYCHIA","source":"FDA FAERS","actionTaken":"351 reports"},{"date":"","signal":"DEHYDRATION","source":"FDA FAERS","actionTaken":"315 reports"}],"drugInteractions":[{"url":"/drug/p-glycoprotein-substrates","drug":"P-glycoprotein Substrates","action":"Use caution","effect":"P-glycoprotein Inhibitors - P-glycoprotein Substrates","source":"DrugCentral","drugSlug":"p-glycoprotein-substrates"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Stomatitis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Rash/acneiform dermatitis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Paronychia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dry skin","drugRate":"3.1%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"4.8%","severity":"serious","_validated":true},{"effect":"Dyspnea","drugRate":"1.7%","severity":"serious","_validated":true},{"effect":"Fatigue","drugRate":"1.7%","severity":"serious","_validated":true},{"effect":"Hypokalemia","drugRate":"1.7%","severity":"serious","_validated":true},{"effect":"Pulmonary toxicity/ILD-like adverse reactions","drugRate":"1.3%","severity":"serious","_validated":true},{"effect":"Sepsis","drugRate":"0.43%","severity":"serious","_validated":true},{"effect":"Pneumonia","drugRate":"0.43%","severity":"serious","_validated":true},{"effect":"Pyrexia","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Conjunctivitis","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Epistaxis","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Rhinorrhea","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Decreased appetite","drugRate":"29%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"25%","severity":"common","_validated":true},{"effect":"Cystitis","drugRate":"1.3%","severity":"mild","_validated":true},{"effect":"Weight decreased","drugRate":"1.7%","severity":"mild","_validated":true},{"effect":"Cheilitis","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Skin and subcutaneous tissue disorders","drugRate":"reported","severity":"unknown"},{"effect":"Infections","drugRate":"reported","severity":"unknown"},{"effect":"Respiratory, thoracic and mediastinal disorders","drugRate":"reported","severity":"unknown"},{"effect":"Investigations","drugRate":"reported","severity":"unknown"},{"effect":"General disorders and administration site conditions","drugRate":"reported","severity":"unknown"},{"effect":"Eye disorders","drugRate":"reported","severity":"unknown"},{"effect":"Other clinically important adverse reactions","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Lactation":"There are no data on the presence of afatinib in human milk or its effects on the breastfed infant or on milk production. Afatinib was present in the milk of lactating rats (see Data). Because of the potential for serious adverse reactions in breastfed infants from GILOTRIF, advise women not to breastfeed during treatment with GILOTRIF and for weeks after the final dose.","Pregnancy":"GILOTRIF can cause fetal harm when administered to pregnant woman. There are no available data on the use of GILOTRIF in pregnant women. Administration of afatinib to pregnant rabbits during organogenesis at exposures approximately 0.2 times the exposure in humans at the recommended dose of 40 mg daily resulted in embryotoxicity and, in rabbits showing maternal toxicity, increased abortions at late gestational stages. Advise pregnant woman of the potential risk to fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.","Geriatric use":"LUX-Lung did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.In LUX-Lung 8, 53% of the 398 patients randomized to receive afatinib were 65 years of age or older and 11% were 75 years or older. In an exploratory subgroup analysis of LUX-Lung 8, the hazard ratio for overall survival (OS) in patients less than 65 years old was 0.68 (95% CI: 0.55, 0.85) and in patients 65 years or older was 0.95 (95% CI: 0.77, 1.18).","Paediatric use":"Safety and effectiveness of GILOTRIF in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Boehringer Ingelheim","patents":[{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Nov 9, 2026","useCode":"U-1950","territory":"US","drugProduct":false,"patentNumber":"9539258","drugSubstance":false},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Dec 19, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8545884","drugSubstance":false},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Oct 10, 2029","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8426586","drugSubstance":true},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Jan 13, 2026","useCode":"","territory":"US","drugProduct":false,"patentNumber":"RE43431","drugSubstance":true},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Jul 5, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10004743","drugSubstance":false},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Jun 19, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8545884*PED","drugSubstance":false},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Apr 10, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8426586*PED","drugSubstance":false},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Jul 13, 2026","useCode":"","territory":"US","drugProduct":false,"patentNumber":"RE43431*PED","drugSubstance":false},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"Jan 5, 2031","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10004743*PED","drugSubstance":false},{"applNo":"N201292","source":"FDA Orange Book","status":"Active","expires":"May 9, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9539258*PED","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=afatinib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:55:25.184923+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:55:18.949687+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Afatinib","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:55:33.341716+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:55:31.956306+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:55:25.205454+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:55:17.318079+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=afatinib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:55:32.778356+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:55:16.198432+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:55:16.198478+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:55:16.198488+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:55:34.252027+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Receptor protein-tyrosine kinase erbB-4 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:55:33.341146+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105712/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:55:33.224459+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA201292","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:55:16.198493+00:00"}},"allNames":"gilotrif","offLabel":[],"synonyms":["afatinib","tovok","afatinib dimaleate","gilotrif","BIBW2992","afatinib maleate"],"timeline":[{"date":"2013-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BOEHRINGER INGELHEIM to Boehringer Ingelheim"},{"date":"2013-07-12","type":"positive","source":"DrugCentral","milestone":"FDA approval (Boehringer Ingelheim)"},{"date":"2013-09-25","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2026-01-13","type":"negative","source":"FDA Orange Book","milestone":"Substance patent RE43431 expires"},{"date":"2029-10-10","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8426586 expires"}],"aiSummary":"Gilotrif is a medication used to treat non-small cell lung carcinoma (NSCLC). It is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) and works by blocking the activity of the EGFR protein.","brandName":"Gilotrif","ecosystem":[{"indication":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","otherDrugs":[{"name":"dacomitinib","slug":"dacomitinib","company":"Pfizer Inc"},{"name":"gefitinib","slug":"gefitinib","company":""},{"name":"osimertinib","slug":"osimertinib","company":"Astrazeneca Pharms"}],"globalPrevalence":2200000}],"mechanism":{"target":"Epidermal growth factor receptor","novelty":"Follow-on","targets":[{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"ERBB2","source":"DrugCentral","target":"Receptor tyrosine-protein kinase erbB-2","protein":"Receptor tyrosine-protein kinase erbB-2"},{"gene":"ERBB4","source":"DrugCentral","target":"Receptor tyrosine-protein kinase erbB-4","protein":"Receptor tyrosine-protein kinase erbB-4"},{"gene":"GAK","source":"DrugCentral","target":"Cyclin-G-associated kinase","protein":"Cyclin-G-associated kinase"},{"gene":"BLK","source":"DrugCentral","target":"Tyrosine-protein kinase Blk","protein":"Tyrosine-protein kinase Blk"},{"gene":"ABL1","source":"DrugCentral","target":"Tyrosine-protein kinase ABL1","protein":"Tyrosine-protein kinase ABL1"},{"gene":"IRAK1","source":"DrugCentral","target":"Interleukin-1 receptor-associated kinase 1","protein":"Interleukin-1 receptor-associated kinase 1"},{"gene":"EPHA6","source":"DrugCentral","target":"Ephrin type-A receptor 6","protein":"Ephrin type-A receptor 6"},{"gene":"HIPK4","source":"DrugCentral","target":"Homeodomain-interacting protein kinase 4","protein":"Homeodomain-interacting protein kinase 4"},{"gene":"PHKG2","source":"DrugCentral","target":"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform","protein":"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform"}],"moaClass":"Protein Kinase Inhibitors","modality":"Small Molecule","drugClass":"Kinase Inhibitor [EPC]","explanation":"Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the absence of ligand binding, and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those occurring in exons constituting the kinase domain of EGFR that lead to increased receptor activation and where efficacy is predicted by 1) clinically meaningful tumor shrinkage with the recommended dose of afatinib and/or 2) inhibition of cellular proliferation or EGFR tyrosine kinase phosphorylation at concentrations of afatinib sustainable at the recommended dosage according to validated methods. The most commonly found of these mutations are exon 21 L","oneSentence":"Gilotrif works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow.","technicalDetail":"Gilotrif (afatinib) is a potent, irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the signaling pathways that regulate cell proliferation, survival, and migration."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Afatinib","title":"Afatinib","extract":"Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth."},"commercial":{"launchDate":"2013","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2013-07-12, BOEHRINGER INGELHEIM)","annualRevenue":400,"revenueSource":"Boehringer Ingelheim FY2024 (Gilotrif)","revenueCurrency":"USD"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4318","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=afatinib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=afatinib","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Afatinib","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:29:46.479433","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:55:40.371651+00:00","fieldsConflicting":9,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"gefitinib","drugSlug":"gefitinib","fdaApproval":"2003-05-05","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"erlotinib","drugSlug":"erlotinib","fdaApproval":"2004-11-18","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"osimertinib","drugSlug":"osimertinib","fdaApproval":"2015-11-13","patentExpiry":"Nov 26, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dacomitinib","drugSlug":"dacomitinib","fdaApproval":"2018-09-27","patentExpiry":"Sep 27, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mobocertinib","drugSlug":"mobocertinib","fdaApproval":"2021-09-15","patentExpiry":"May 13, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"afatinib","indications":{"approved":[{"name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","source":"DrugCentral","snomedId":426964009,"regulator":"FDA","usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"}],"offLabel":[],"pipeline":[]},"currentOwner":"Boehringer Ingelheim","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"gefitinib","brandName":"gefitinib","genericName":"gefitinib","approvalYear":"2003","relationship":"same-class"},{"drugId":"erlotinib","brandName":"erlotinib","genericName":"erlotinib","approvalYear":"2004","relationship":"same-class"},{"drugId":"osimertinib","brandName":"osimertinib","genericName":"osimertinib","approvalYear":"2015","relationship":"same-class"},{"drugId":"dacomitinib","brandName":"dacomitinib","genericName":"dacomitinib","approvalYear":"2018","relationship":"same-class"},{"drugId":"mobocertinib","brandName":"mobocertinib","genericName":"mobocertinib","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00949650","phase":"PHASE3","title":"BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2009-08-14","conditions":["Carcinoma, Non-Small-Cell Lung","Adenocarcinoma"],"enrollment":345,"completionDate":"2017-03-16"},{"nctId":"NCT00525148","phase":"PHASE2","title":"LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2007-08","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":129,"completionDate":"2015-08"},{"nctId":"NCT01121393","phase":"PHASE3","title":"BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2010-04-19","conditions":["Carcinoma, Non-Small-Cell Lung","Adenocarcinoma"],"enrollment":364,"completionDate":"2017-11-26"},{"nctId":"NCT01523587","phase":"PHASE3","title":"LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2012-03-05","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":795,"completionDate":"2017-12-27"},{"nctId":"NCT06385483","phase":"PHASE2","title":"Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-28","conditions":["Advanced Lymphoma","Advanced Malignant Solid Neoplasm","Refractory Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Multiple Myeloma"],"enrollment":19,"completionDate":"2027-01-15"},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":["Advanced Lymphoma","Advanced Malignant Solid Neoplasm","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colon Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Esophageal Carcinoma","Exocrine Pancreas Carcinoma","Gastric Carcinoma","Glioma","Head and Neck Carcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Kidney Carcinoma","Liver Carcinoma","Lung Carcinoma","Lymphoma","Malignant Uterine Corpus Neoplasm","Malignant Uterine Neoplasm","Melanoma","Multiple Myeloma","Ovarian Carcinoma","Prostate Carcinoma","Rectal Carcinoma","Recurrent Bladder Carcinoma","Recurrent Breast Carcinoma","Recurrent Cervical Carcinoma","Recurrent Colon Carcinoma","Recurrent Colorectal Carcinoma","Recurrent Esophageal Carcinoma","Recurrent Gastric Carcinoma","Recurrent Glioma","Recurrent Head and Neck Carcinoma","Recurrent Liver Carcinoma","Recurrent Lung Carcinoma","Recurrent Lymphoma","Recurrent Malignant Solid Neoplasm","Recurrent Malignant Uterine Corpus Neoplasm","Recurrent Melanoma","Recurrent Multiple Myeloma","Recurrent Ovarian Carcinoma","Recurrent Pancreatic Carcinoma","Recurrent Prostate Carcinoma","Recurrent Rectal Carcinoma","Recurrent Skin Carcinoma","Recurrent Thyroid Gland Carcinoma","Refractory Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Multiple Myeloma","Skin Carcinoma","Thyroid Gland Carcinoma"],"enrollment":6452,"completionDate":"2026-12-31"},{"nctId":"NCT01783587","phase":"PHASE1","title":"Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-02","conditions":["Squamous Cell Carcinoma of the Head and Neck"],"enrollment":29,"completionDate":"2018-06-01"},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":["Non-Small-Cell Lung Cancer","Metastatic Non-Small-Cell Lung Cancer","Advanced Non-Small-Cell Lung Cancer","EGFR P-Loop and Alpha C-Helix Compressing","EGFR PACC","EGFR Uncommon Mutations"],"enrollment":480,"completionDate":"2030-12"},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":["Non-Small Cell Lung Cancer (NSCLC)","Metastatic Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer","HER2 Exon 20 Mutations","EGFR Exon 20 Mutations","EGFR Uncommon Mutations, Including G719X and S768I"],"enrollment":160,"completionDate":"2026-12-31"},{"nctId":"NCT02438722","phase":"PHASE2,PHASE3","title":"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2015-05-07","conditions":["Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer"],"enrollment":174,"completionDate":"2026-12-31"},{"nctId":"NCT02979977","phase":"PHASE2","title":"Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-03-24","conditions":["Squamous Cell Cancers of the Head and Neck"],"enrollment":50,"completionDate":"2026-01-18"},{"nctId":"NCT05070403","phase":"PHASE2","title":"Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-01","conditions":["Squamous Cell Carcinoma"],"enrollment":25,"completionDate":"2028-03"},{"nctId":"NCT06302621","phase":"PHASE1","title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-04-17","conditions":["Advanced Solid Tumor","Unresectable Solid Tumor","Metastatic Solid Tumor","Cholangiocarcinoma"],"enrollment":70,"completionDate":"2027-12-01"},{"nctId":"NCT01856478","phase":"PHASE3","title":"LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-06-07","conditions":["Head and Neck Neoplasms"],"enrollment":340,"completionDate":"2024-10-02"},{"nctId":"NCT06494189","phase":"PHASE1","title":"Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2024-07-31","conditions":["Head and Neck Cancer"],"enrollment":9,"completionDate":"2025-04-10"},{"nctId":"NCT07040956","phase":"PHASE2","title":"A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-28","conditions":["Head and Neck Squamous Cell Carcinoma","Low-dose Radiotherapy","Immunotherapy","Targeted Therapy"],"enrollment":98,"completionDate":"2026-07-01"},{"nctId":"NCT06085755","phase":"PHASE1,PHASE2","title":"Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Jeeyun Lee","startDate":"2024-09-30","conditions":["Stomach Neoplasm"],"enrollment":61,"completionDate":"2026-12"},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":["Non-small Cell Lung Cancer"],"enrollment":8,"completionDate":"2023-12-01"},{"nctId":"NCT07267247","phase":"","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2022-06-01","conditions":["Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)","Drug-Related Side Effects and Adverse Reactions (MeSH Term)","Egfr Tyrosine Kinase Inhibitor","Cardiotoxicity"],"enrollment":100,"completionDate":"2024-04-30"},{"nctId":"NCT06753747","phase":"PHASE1,PHASE2","title":"A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-10","conditions":["Esophagus Cancer"],"enrollment":45,"completionDate":"2028-09"},{"nctId":"NCT06804850","phase":"PHASE2","title":"Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC","status":"WITHDRAWN","sponsor":"West China Hospital","startDate":"2025-01-20","conditions":["Head and Neck Cancer"],"enrollment":0,"completionDate":"2026-06-30"},{"nctId":"NCT06897735","phase":"PHASE1","title":"Exploratory Study of Inhaled Afatinib Dimaleate PK Profile","status":"NOT_YET_RECRUITING","sponsor":"Petrov, Andrey","startDate":"2025-11-09","conditions":["Lung Cancer","Oral Cancer","Melanoma"],"enrollment":24,"completionDate":"2026-05-07"},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":["Advanced Solid Tumors","Kirsten Rat Sarcoma (KRAS) pG12C Mutation"],"enrollment":610,"completionDate":"2027-12-05"},{"nctId":"NCT02491099","phase":"PHASE2","title":"A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma","status":"RECRUITING","sponsor":"Yale University","startDate":"2015-06","conditions":["HER2/Neu+ Uterine Serous Carcinoma"],"enrollment":50,"completionDate":"2028-07"},{"nctId":"NCT04497584","phase":"PHASE2","title":"Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-08-04","conditions":["Advanced Squamous Non Small Cell Lung Cancer"],"enrollment":12,"completionDate":"2027-09-01"},{"nctId":"NCT03785249","phase":"PHASE1,PHASE2","title":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2019-01-15","conditions":["Advanced Cancer","Metastatic Cancer","Malignant Neoplastic Disease"],"enrollment":731,"completionDate":"2026-12-31"},{"nctId":"NCT05588609","phase":"PHASE2","title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","status":"TERMINATED","sponsor":"Merus B.V.","startDate":"2022-11-17","conditions":["NSCLC Harboring NRG1 Fusion","Metastatic Castration-resistant Prostate Cancer"],"enrollment":13,"completionDate":"2025-07-03"},{"nctId":"NCT04439136","phase":"PHASE2","title":"Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":["Advanced Lymphoma","Advanced Malignant Solid Neoplasm","Hematopoietic and Lymphoid Cell Neoplasm","Refractory Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Multiple Myeloma"],"enrollment":40,"completionDate":"2026-03-17"},{"nctId":"NCT00716417","phase":"PHASE1","title":"Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-07-01","conditions":["Neoplasms"],"enrollment":47,"completionDate":"2010-07-01"},{"nctId":"NCT05517330","phase":"PHASE2","title":"Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-19","conditions":["Head and Neck Cancer"],"enrollment":23,"completionDate":"2024-07-31"},{"nctId":"NCT06062823","phase":"PHASE2","title":"Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-03-25","conditions":["NSCLC"],"enrollment":35,"completionDate":"2026-12"},{"nctId":"NCT06709859","phase":"PHASE2","title":"Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC","status":"RECRUITING","sponsor":"Shandong Public Health Clinical Center","startDate":"2025-05-01","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT02191891","phase":"PHASE1","title":"Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-10-21","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":32,"completionDate":"2018-04-18"},{"nctId":"NCT07036016","phase":"","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-01-01","conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"enrollment":67818,"completionDate":"2025-05-01"},{"nctId":"NCT07010120","phase":"PHASE1,PHASE2","title":"A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-10","conditions":["HNSCC","Lysogenic HSV Virus","Neoadjuvant Therapy","Immunotherapy","Targeted Therapy"],"enrollment":29,"completionDate":"2027-05-31"},{"nctId":"NCT05516589","phase":"PHASE2","title":"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-12","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":40,"completionDate":"2024-12-31"},{"nctId":"NCT01880515","phase":"PHASE2","title":"Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2010-12","conditions":["Skin Rash","Lung Cancer"],"enrollment":107,"completionDate":"2014-11"},{"nctId":"NCT05432518","phase":"EARLY_PHASE1","title":"Pilot Trial for Treatment of Recurrent Glioblastoma","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-06-27","conditions":["Glioblastoma","Recurrent Disease","Recurrent Glioblastoma"],"enrollment":10,"completionDate":"2027-12-01"},{"nctId":"NCT02122172","phase":"PHASE2","title":"Afatinib in Advanced Refractory Urothelial Cancer","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2017-09-13","conditions":["Distal Urethral Cancer","Proximal Urethral Cancer","Recurrent Bladder Cancer","Recurrent Urethral Cancer","Stage III Bladder Cancer","Stage III Urethral Cancer","Stage IV Bladder Cancer","Stage IV Urethral Cancer","Ureter Cancer"],"enrollment":32,"completionDate":"2024-04-04"},{"nctId":"NCT01853826","phase":"PHASE3","title":"An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07-17","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":481,"completionDate":"2024-03-06"},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":["Non-Small Cell Lung Cancer"],"enrollment":5279,"completionDate":"2024-01-23"},{"nctId":"NCT05298176","phase":"PHASE2","title":"Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2022-01-04","conditions":["Non-Small Cell Lung Cancer"],"enrollment":5,"completionDate":"2024-04-01"},{"nctId":"NCT04413201","phase":"PHASE4","title":"AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Hopp","startDate":"2020-09-11","conditions":["Non-squamous NSCLC"],"enrollment":34,"completionDate":"2026-12-31"},{"nctId":"NCT04206787","phase":"","title":"The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-05-20","conditions":["Non-squamous, Non-Small Cell Lung Cancer"],"enrollment":72,"completionDate":"2023-12-22"},{"nctId":"NCT02424617","phase":"PHASE1,PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":["Non-Small Cell Lung Cancer"],"enrollment":40,"completionDate":"2021-08-25"},{"nctId":"NCT05215548","phase":"PHASE2","title":"Primary Tumor Resection With EGFR TKI for Stage IV NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-09-27","conditions":["NSCLC Stage IV"],"enrollment":100,"completionDate":"2027-10"},{"nctId":"NCT02597946","phase":"PHASE2","title":"Afatinib in NSCLC With HER2 Mutation","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-18","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":18,"completionDate":"2018-07-22"},{"nctId":"NCT03083678","phase":"PHASE2","title":"Afatinib in Locally Advanced and Metastatic Chordoma","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2018-06-21","conditions":["Chordoma"],"enrollment":43,"completionDate":"2025-01-31"},{"nctId":"NCT00748709","phase":"PHASE2","title":"Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-10-01","conditions":["Neoplasms"],"enrollment":20,"completionDate":""},{"nctId":"NCT01649271","phase":"PHASE1","title":"Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07-23","conditions":["Breast Neoplasms","Stomach Neoplasms"],"enrollment":13,"completionDate":"2016-06-23"},{"nctId":"NCT00950742","phase":"PHASE1","title":"Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-08-01","conditions":["Breast Neoplasms"],"enrollment":18,"completionDate":"2013-10-01"},{"nctId":"NCT01214616","phase":"PHASE1","title":"BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-10-01","conditions":["Neoplasms"],"enrollment":17,"completionDate":"2013-05-01"},{"nctId":"NCT02171650","phase":"PHASE1","title":"BIBW 2992 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-12-01","conditions":["Neoplasms"],"enrollment":7,"completionDate":""},{"nctId":"NCT06071013","phase":"PHASE1,PHASE2","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2024-02-23","conditions":["Non-small Cell Lung Cancer","EGFR Gene Mutation","EGFR-TKI Resistant Mutation"],"enrollment":20,"completionDate":"2026-08-27"},{"nctId":"NCT06759857","phase":"PHASE3","title":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","startDate":"2021-08-01","conditions":["Non Small Cell Lung Cancer"],"enrollment":350,"completionDate":"2025-05-01"},{"nctId":"NCT02951091","phase":"NA","title":"Biomarker-Integrated Umbrella, Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-01-01","conditions":["Gastric Cancer"],"enrollment":400,"completionDate":"2024-03"},{"nctId":"NCT04795245","phase":"","title":"Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-08-26","conditions":["Non-squamous, Non-Small Cell Lung Cancer"],"enrollment":805,"completionDate":"2023-10-16"},{"nctId":"NCT06741982","phase":"PHASE1","title":"A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-15","conditions":["HNSCC","Lysogenic HSV Virus","Neoadjuvant Therapy","Immunotherapy","Targeted Therapy"],"enrollment":21,"completionDate":"2026-12-15"},{"nctId":"NCT01553942","phase":"PHASE2","title":"Afatinib With CT and RT for EGFR-Mutant NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2012-04","conditions":["Lung Cancer"],"enrollment":19,"completionDate":"2024-12"},{"nctId":"NCT06648096","phase":"PHASE1,PHASE2","title":"Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2024-11-08","conditions":["Fanconi Anemia","Head and Neck Squamous Cell Carcinoma"],"enrollment":25,"completionDate":"2028-12"},{"nctId":"NCT02364609","phase":"PHASE1","title":"Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib","status":"COMPLETED","sponsor":"Jonathan Riess","startDate":"2015-09-30","conditions":["Recurrent Non-Small Cell Lung Carcinoma","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer"],"enrollment":11,"completionDate":"2020-05-01"},{"nctId":"NCT04183712","phase":"PHASE2","title":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-06-01","conditions":["Gallbladder Carcinoma"],"enrollment":102,"completionDate":"2025-12"},{"nctId":"NCT04750824","phase":"","title":"Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-10-15","conditions":["Non-squamous, Non-Small Cell Lung Cancer"],"enrollment":110,"completionDate":"2021-12-20"},{"nctId":"NCT04839471","phase":"PHASE2","title":"BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-08-06","conditions":["Esophageal Squamous Cell Carcinoma (ESCC)"],"enrollment":49,"completionDate":"2024-06-19"},{"nctId":"NCT06486142","phase":"PHASE3","title":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","status":"RECRUITING","sponsor":"Region Skane","startDate":"2022-09-21","conditions":["Non-Small Cell Lung Cancer"],"enrollment":200,"completionDate":"2028-09"},{"nctId":"NCT04909073","phase":"","title":"Observational Study of Afatinib 30 mg Daily","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2022-10-25","conditions":["Non-Small Cell Lung Cancer","Epidermal Growth Factor Receptor Mutation"],"enrollment":69,"completionDate":"2025-12"},{"nctId":"NCT04410653","phase":"PHASE2","title":"Afatinib in Advanced NRG1-Rearranged Malignancies","status":"COMPLETED","sponsor":"German Cancer Research Center","startDate":"2022-07-31","conditions":["Metastatic and Locally Advanced NRG1-rearranged Malignancies"],"enrollment":3,"completionDate":"2023-10-04"},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Anatomic Stage IV Breast Cancer AJCC v8","Anemia","Ann Arbor Stage III Hodgkin Lymphoma","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Castration-Resistant Prostate Carcinoma","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Hematopoietic and Lymphoid System Neoplasm","Locally Advanced Pancreatic Adenocarcinoma","Metastatic Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Pancreatic Adenocarcinoma","Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis","Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable","Primary Myelofibrosis","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Recurrent Chronic Lymphocytic Leukemia","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hematologic Malignancy","Recurrent Hodgkin Lymphoma","Recurrent Myelodysplastic Syndrome","Recurrent Myelodysplastic/Myeloproliferative Neoplasm","Recurrent Myeloproliferative Neoplasm","Recurrent Non-Hodgkin Lymphoma","Recurrent Plasma Cell Myeloma","Recurrent Small Lymphocytic Lymphoma","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Chronic Lymphocytic Leukemia","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Chronic Myelomonocytic Leukemia","Refractory Hematologic Malignancy","Refractory Hodgkin Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Myelodysplastic Syndrome","Refractory Myelodysplastic/Myeloproliferative Neoplasm","Refractory Non-Hodgkin Lymphoma","Refractory Plasma Cell Myeloma","Refractory Primary Myelofibrosis","Refractory Small Lymphocytic Lymphoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma"],"enrollment":2,"completionDate":"2020-12-10"},{"nctId":"NCT01542437","phase":"PHASE2","title":"Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2012-01","conditions":["Non-Small Cell Lung Cancer","EGFR","HER-2"],"enrollment":66,"completionDate":"2017-06"},{"nctId":"NCT02768337","phase":"PHASE1,PHASE2","title":"Cambridge Brain Mets Trial 1","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2015-03-10","conditions":["Lung Cancer","Breast Cancer","Brain Cancer","Advanced Breast Cancer","Advanced Lung Cancer"],"enrollment":26,"completionDate":"2021-08-12"},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":["Cancer","Tumors","Neoplasm","Neoplasia"],"enrollment":1550,"completionDate":"2027-12"},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":878,"completionDate":"2026-03-30"},{"nctId":"NCT02795156","phase":"PHASE2","title":"Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2016-09-28","conditions":["Non-small Cell Lung Carcinoma","Urothelial Carcinoma","Gastrointestinal Carcinoma, Non-colon","Upper Aerodigestive Tract Carcinoma"],"enrollment":100,"completionDate":"2022-08-17"},{"nctId":"NCT02183883","phase":"PHASE2","title":"Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity","status":"COMPLETED","sponsor":"University College, London","startDate":"2016-12-16","conditions":["Non-small Cell Lung Cancer"],"enrollment":12,"completionDate":"2023-03-22"},{"nctId":"NCT03088059","phase":"PHASE2","title":"Biomarker-based Study in R/M SCCHN","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-11-16","conditions":["Carcinoma, Squamous Cell of Head and Neck"],"enrollment":340,"completionDate":"2025-12"},{"nctId":"NCT01522768","phase":"PHASE2","title":"Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-03","conditions":["Esophageal Cancer","Gastric Cancer"],"enrollment":42,"completionDate":"2023-02-20"},{"nctId":"NCT03727724","phase":"PHASE2","title":"Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-12-04","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":37,"completionDate":"2022-09-06"},{"nctId":"NCT02506517","phase":"PHASE2","title":"A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-08","conditions":["Solid Tumors"],"enrollment":12,"completionDate":"2023-05-04"},{"nctId":"NCT05927844","phase":"PHASE1","title":"XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-06","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":20,"completionDate":"2025-06"},{"nctId":"NCT01824823","phase":"PHASE2","title":"Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2014-06-30","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":3,"completionDate":"2020-12"},{"nctId":"NCT05445791","phase":"PHASE3","title":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2021-07-15","conditions":["Non Small Cell Lung Cancer"],"enrollment":312,"completionDate":"2025-07-14"},{"nctId":"NCT04179890","phase":"","title":"The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-17","conditions":["Non-squamous, Non-Small Cell Lung Cancer"],"enrollment":462,"completionDate":"2021-07-22"},{"nctId":"NCT05865132","phase":"PHASE2","title":"Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction","status":"RECRUITING","sponsor":"AIPING ZHOU","startDate":"2023-04-06","conditions":["Esophagus Squamous Cell Carcinoma"],"enrollment":30,"completionDate":"2026-04"},{"nctId":"NCT03115567","phase":"PHASE2","title":"A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-02-16","conditions":["Acneiform Rash","Papulopustular Eruption"],"enrollment":14,"completionDate":"2022-09-02"},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":["Carcinoma, Non-Small-Cell Lung","Synchronous Neoplasms"],"enrollment":36,"completionDate":"2019-01"},{"nctId":"NCT03827070","phase":"PHASE1","title":"Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma","status":"UNKNOWN","sponsor":"Center Trials & Treatment Europe","startDate":"2019-03-05","conditions":["Non Small Cell Lung Cancer"],"enrollment":12,"completionDate":"2023-07-21"},{"nctId":"NCT05818982","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-02-09","conditions":["Advanced Esophageal Squamous Cell Carcinoma"],"enrollment":72,"completionDate":"2026-02"},{"nctId":"NCT05267288","phase":"PHASE2","title":"Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qingdao Central Hospital","startDate":"2021-02-01","conditions":["PFS"],"enrollment":30,"completionDate":"2025-06-01"},{"nctId":"NCT02501603","phase":"PHASE2","title":"Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-07","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"enrollment":72,"completionDate":"2022-12-20"},{"nctId":"NCT04201756","phase":"PHASE2","title":"Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-07-26","conditions":["Lung Adenocarcinoma Stage III","EGFR Gene Mutation"],"enrollment":47,"completionDate":"2022-08-30"},{"nctId":"NCT03574402","phase":"PHASE2","title":"Phase II Umbrella Study Directed by Next Generation Sequencing","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2018-07-09","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":400,"completionDate":"2024-12-30"},{"nctId":"NCT05107193","phase":"","title":"Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)","status":"NO_LONGER_AVAILABLE","sponsor":"Boehringer Ingelheim","startDate":"","conditions":["Solid Tumors"],"enrollment":0,"completionDate":""},{"nctId":"NCT05519917","phase":"PHASE2","title":"Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-10-01","conditions":["Chordoma of Clivus"],"enrollment":20,"completionDate":"2025-12-30"},{"nctId":"NCT02369484","phase":"PHASE2","title":"Afatinib in NSCLC With HER2 Mutation","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2015-09-16","conditions":["NSCLC"],"enrollment":13,"completionDate":"2017-09-15"},{"nctId":"NCT03908892","phase":"NA","title":"Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib","status":"UNKNOWN","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2019-06-12","conditions":["Paronychia"],"enrollment":110,"completionDate":"2022-12"},{"nctId":"NCT02716311","phase":"PHASE2","title":"Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2016-05","conditions":["Non Small Cell Lung Cancer"],"enrollment":118,"completionDate":"2021-04-07"},{"nctId":"NCT05467189","phase":"","title":"Antineoplastic Drugs in Elderly Patients","status":"RECRUITING","sponsor":"Shandong University","startDate":"2021-01-01","conditions":["Cancer"],"enrollment":500,"completionDate":"2028-06-30"},{"nctId":"NCT01320280","phase":"PHASE2","title":"BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2011-05","conditions":["Refractory Cancer"],"enrollment":29,"completionDate":"2012-11"},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":["Recurrent Acute Leukemia of Ambiguous Lineage","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Acute Leukemia of Ambiguous Lineage"],"enrollment":34,"completionDate":"2021-05-13"},{"nctId":"NCT03623750","phase":"PHASE1,PHASE2","title":"E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C","status":"COMPLETED","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2018-07-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":23,"completionDate":"2021-12-14"},{"nctId":"NCT03711422","phase":"PHASE1","title":"Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC","status":"TERMINATED","sponsor":"National Cancer Centre, Singapore","startDate":"2018-11-16","conditions":["Non-small Cell Lung Cancer","Leptomeningeal Disease","Central Nervous System Metastases"],"enrollment":2,"completionDate":"2019-12-20"},{"nctId":"NCT02451553","phase":"PHASE1","title":"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-11-05","conditions":["Advanced Malignant Solid Neoplasm","Bile Duct Carcinoma","Recurrent Malignant Solid Neoplasm","Recurrent Pancreatic Carcinoma","Stage III Pancreatic Cancer AJCC v6 and v7","Stage IVA Pancreatic Cancer","Stage IVB Pancreatic Cancer"],"enrollment":41,"completionDate":"2022-04-16"},{"nctId":"NCT02440854","phase":"","title":"Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-02-16","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":80,"completionDate":"2021-02-17"},{"nctId":"NCT03695510","phase":"PHASE2","title":"Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-01-24","conditions":["Head and Neck Neoplasms"],"enrollment":29,"completionDate":"2022-04-14"}],"_emaApprovals":[{"date":"2013-09-25","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT00949650","NCT00525148","NCT01121393","NCT01523587"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Gilotrif"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000188388","MMSL":"204142","NDDF":"015117","UNII":"41UD74L59M","VUID":"4032662","CHEBI":"CHEBI:61390","VANDF":"4032662","INN_ID":"9230","RXNORM":"1430268","UMLSCUI":"C2987648","chemblId":"CHEMBL2105712","ChEMBL_ID":"CHEMBL1173655","KEGG_DRUG":"D09724","DRUGBANK_ID":"DB08916","PDB_CHEM_ID":" 0WM","PUBCHEM_CID":"10184653","SNOMEDCT_US":"703579002","IUPHAR_LIGAND_ID":"5667","SECONDARY_CAS_RN":"850140-73-7","MESH_DESCRIPTOR_UI":"D000077716"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Boehringer Ingelheim Pharmaceuticals, Inc.","brandName":"Gilotrif","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2013-","companyName":"Boehringer Ingelheim","relationship":"Original Developer"}],"pharmacokinetics":{"source":"FDA label","halfLife":"37 hours"},"publicationCount":2479,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-03-31 10:32:16.016033+00","atcClassification":{"source":"DrugCentral","atcCode":"L01EB03","allCodes":["L01EB03"]},"biosimilarFilings":[],"originalDeveloper":"Boehringer Ingelheim","recentPublications":[{"date":"2026 Mar 25","pmid":"41882274","title":"TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations.","journal":"Communications medicine"},{"date":"2026","pmid":"41878697","title":"Fatal Disease Progression Driven by Acquired MET Amplification After EGFR-TKI Therapy in EGFR- and RBM10-Mutant Lung Adenocarcinoma.","journal":"Cancer management and research"},{"date":"2026 Mar 15","pmid":"41875675","title":"Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation.","journal":"Bioorganic & medicinal chemistry"},{"date":"2026 Mar 24","pmid":"41874451","title":"The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer.","journal":"Cancer discovery"},{"date":"2026 Mar 23","pmid":"41872782","title":"EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.","journal":"BMC cancer"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Boehringer Ingelheim","companyId":"boehringer-ingelheim","modality":"Small Molecule","firstApprovalDate":"2013","enrichmentLevel":4,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2013-09-25T00:00:00.000Z","mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-10-04T00:00:00.000Z","mah":"BOEHRINGER INGELHEIM","brand_name_local":null,"application_number":"NDA201292"},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":15,"withResults":11},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:55:40.371651+00:00","fieldsConflicting":9,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}